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 ABSTRACT 
    HIV-1 protease is a very important drug target for AIDS therapy. Nine protease 
inhibitors have been proved by FDA and used in AIDS treatment. Due to the high 
replication rate and the lack of fidelity of the HIV-1 reverse transcriptase, HIV-1 virus 
developed various drug-resistant variants. Although experimental methods such as 
crystallography and isothermal titration calorimetry provide structural and 
thermodynamic data on drug-resistant variants, they are unable to discern the 
mechanism by which the mutations confer resistance to inhibitors. Understanding the 
drug-resistance mechanism is crucial for developing new inhibitors more tolerant to 
the drug-resistant mutations. Computational methods such as free energy calculations 
and molecular dynamic simulations can provide insights to the drug resistance 
mechanism at an atomic level. In this thesis, I have focused on the elucidation of the 
energetic and dynamics of key drug-resistant variants of HIV-1 protease.  
Two multi-drug resistant variants, in comparison with wild-type HIV-1 protease 
were used for the comparisons:  Flap+ (L10I, G48V, I54V, and V82A) which 
contains a combination of flap and active site mutations and ACT (V82T, I84V) that 
only contains active site mutations. In Chapter II, I applied free energy simulations 
and decomposition methods to study the differential mechanism of resistance to the 
two variants, Flap+ and ACT, to the recently FDA-approved protease inhibitor 
darunavir (DRV). In this study, the absolute and relative binding free energies of 
DRV with wild-type protease and the two protease variants were calculated with 
MM-PB/GBSA and thermodynamic integration methods, respectively. And the 
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predicted results are in good agreement with the ITC experimental results. Free 
energy decomposition elucidates the mutations alter not only its own interaction with 
DRV but also other residues by changing the geometry of binding pocket. And the 
VdW interactions between the bis-THF group of DRV is predominant even in the 
drug-resistant variants. At the end of this chapter, I offer suggestions on developing 
new inhibitors that are based on DRV but might be less susceptible to drug-resistant 
mutations. 
In Chapter III, 20-ns MD simulations of the apo wildtype protease and the apo 
drug-resistant protease variant Flap+ are analyzed and compared. In these studies, 
these mutations have been found to decrease the protease flexibility in the apo form 
but increase the mobility when the protease is binding with inhibitor.  
In Chapter IV, more details of the free energy simulation and decomposition are 
discussed. NMR relaxation experiments were set up as a control for the MD 
simulation study of the dynamics of the Flap+ variant. The difficulty of finishing the 
NMR experiment is discussed and the solution and some preliminary results are 
shown. 
In summary, the scope of this thesis was to use computational methods to study 
drug-resistant protease variants’ thermodynamic and dynamic properties to illuminate 
the mechanism of protease drug resistance. This knowledge will contribute to rational 
design of new protease inhibitors which bind more tightly to the protease and hinder 
the development of drug-resistant mutations. 
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Chapter I 
 
Introduction 
 2
Global AIDS Epidemic 
 
The first patient diagnosed with the acquired immunodeficiency syndrome 
(AIDS) was in the United States in 1981. Since then, AIDS has come to attention of 
the medical community and quickly emerged as a public health threat. More than 25 
million people over the world have died of the disease. The immune system of 
patients with the AIDS is weakened by the human immunodeficiency virus (HIV), 
leading to these patients becoming more vulnerable to different kinds of opportunistic 
infections. HIV is transmitted by three major routes: (1) sexual contact, (2) exposure 
to infected bodily fluids, including intravenous drugs, and (3) mother-to-child 
transmission. According to the Joint United Nations Program on HIV/AIDS and the 
World Health Organization AIDS epidemic statistics updated in July 2008 (referring 
to the end of 2007) approximately 33 million people globally are living with HIV 
infection (Figure 1.1). Of the 2.7 million people newly infected with HIV in 2007, 
more than half were people under 25 years old (Table 1.1). These devastating statistics 
shows that AIDS is one of the most urgent public health crises of modern society. 
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Figure 1.1: Global Prevalence of HIV-1 Infections 
 
 
(http://www.avert.org/worldstats.htm) 
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Table 1.1: Global HIV/AIDS estimates by the end of 2007 
(http://www.avert.org/worldstats.htm) 
 Estimate Range 
People living with HIV/AIDS in 2007 33.0 million 30.3-36.1 million 
Adults living with HIV/AIDS in 2007 30.8 million 28.2-34.0 million 
Women living with HIV/AIDS in 2007 15.5 million 14.2-16.9 million 
Children living with HIV/AIDS in 2007 2.0 million 1.9-2.3 million 
People newly infected with HIV in 2007 2.7 million 2.2-3.2 million 
Children newly infected with HIV in 2007 0.37 million 0.33-0.41 million 
AIDS deaths in 2007 2.0 million 1.8-2.3 million 
Child AIDS deaths in 2007 0.27 million 0.25-0.29 million 
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HIV life cycle 
 
HIV, a retrovirus belonging to the Retroviridae family, impairs the human 
immune system by infecting immune cells such as CD4+ cells, macrophages and 
dendritic cells. The virus particle is roughly a sphere with diameter of 120 nm. Unlike 
most bacteria, HIV particles are much too small to be seen through an ordinary 
microscope. However they can be seen clearly with an electron microscope. 
HIV has just nine genes (compared to more than 5,000 genes in a bacterium, 
and 20,000-25,000 in a human), which are encoded by two copies of single-stranded 
RNA which is 9749 nucleotides long. The gag, pol, and env genes carry information 
for the structural proteins (matrix [MA], capsid [CA], P6, and nucleocapsid [NC]), 
two envelope proteins (transmembrane [TM] and surface [SU]), and three enzymes 
(protease [PR], integrase [IN], and reverse transcriptase [RT]), respectively. The tat, 
rev, nef, vif, vpr and vpu genes code for 6 regulatory proteins and enzymes. The viral 
life cycle includes these stages: (1) entry, (2) reverse transcription, (3) integration and 
transcription, (4) translation, (5) budding, and (6) maturation (Figure 1.2).1   
(1) Entry: HIV, an enveloped virus, enters cells by fusing the viral and host cell 
plasma membranes. This process is carried out by the viral envelope proteins SU 
(gp120) and TM (gp41). The SU protein binds to the N-terminal immunoglobulin 
domain of the CD4+ receptor, followed by interactions between the env protein 
and chemokine co-receptor, typically CCR5 or CXCR4. These interactions change 
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the conformation of the TM protein to expose it, facilitating fusion of the viral and 
host cell membranes. Finally, the viral genome is released into the host cell. 
(2) Reverse transcription: After the virus enters the host cell, RT uses the host cell 
machinery to reverse transcribe the viral RNA to generate double-stranded DNA. 
This process is extremely error prone due to HIV RT lacking a proofreading 
mechanism. Thus, this step introduces many mutations into the viral genetic code. 
(3) Integration and transcription: The synthesized double-stranded DNA is transported 
into the host cell nucleus with other viral proteins such as RT and IN. In the host 
cell nucleus, IN inserts viral cDNA into the host cell chromosomes. After 
transcription, the viral mRNA is exported to the cytoplasm. 
(4) Translation: The regulatory proteins Rev and Tat are first translated from sliced 
piece of the viral mRNA. They allow the full-length viral RNA to be transported 
into the cytoplasm. The other viral proteins are expressed from the unspliced 
RNA. 
(5) Budding: Two copies of full-length viral RNA along with structural proteins and 
enzymes in the form of poly-proteins are transported to the host cell plasma 
membrane where TM anchors the SU protein. The forming virion begins to bud 
from the host cell to become an immature noninfectious virion. 
(6) Maturation: PR cleaves the gal and gal-pol polyproteins into individual functional 
HIV proteins and enzymes. The structural components then assemble to produce a 
mature HIV virion which is able to attack another cell. This cleavage step can be 
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inhibited by protease inhibitors. 
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Figure 1.2: Replication cycle of HIV with current and possible targets for 
antiviral intervention. 1 
 
 
 
Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Drug Discovery, 2007. 
www.nature.com/nrd/index.html 
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HIV itor 
 
HIV-1 protease is responsible for the post-translational processing of the viral 
Gag and Gag-Pol polyproteins to yield the structural proteins and enzymes of the 
virus. The enzyme is an aspartic protease composed of two noncovalently-associated, 
structurally identical monomers, 99 amino acids in length. The protease dimer is 
about 22 kDa. Its active site resembles that of other aspartic proteases and contains 
the conserved triad, Asp-Thr-Gly, at positions 25-27 (Figure 1.3). The hydrophobic 
substrate cleft recognizes and cleaves 10 different peptide sequences to produce the 
matrix (MA), capsid (CA), nucleocapsid (NC), and p6 proteins from the Gag 
polyprotein and the protease (PR), reverse transcriptase (RT), and integrase (IN) from 
the Gag-Pol polyprotein.  
HIV-1 protease contains a flexible flap region that closes down on the active 
site upon substrate binding. Due to its importance for viral replication, HIV-1 protease 
has been a prime target of drugs to combat AIDS. There are ten FDA-approved 
protease inhibitors (PIs): amprenavir, atazanavir, fosamprenavir (slow release version 
of amprenavir), indinavir, lopinavir (marketed in combination with ritonavir), 
nelfinavir, ritonavir, saquinavir, tipranavir, and the recently approved darunavir. 
Protease inhibitors have been used in combination with drugs targeting other HIV 
enzymes. This combined treatment has been credited with an approximately 3-fold 
drop in the death rate from AIDS since its introduction in 1995. The development of 
protease and HIV protease inhib
 10
HIV-1 protease inhi tructure-based drug 
design. Indeed, PIs are considered the most potent medications currently available for 
the tre
bitors is regarded as a major success of s
atment of AIDS.  
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Figure 1.3: HIV-1 protease structure. The catalytic residues Asp25 and Asp25’ 
are colored in red 
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Drug-resistant HIV protease mutations 
 
Despite the remarkable success of PIs in treating AIDS, this success is 
iminished largely by the emergence of HIV mutants that resist current therapy. In 
fact, viral resistance is regarded as a critical factor in clinical failure of antiviral 
therapy. The infidelity of HIV-1 reverse transcriptase and the rapid turnover rate of the 
virus leads to a high rate mutation in the viral genome. As a result, some viral genes 
acquire mutations that give the virus a replicative advantage under the selective 
pressure of inhibitors. These mutations result in amino acid substitutions in the 
protease that reduce its binding affinity for the inhibitors, yet maintain sufficient 
substrate binding and catalysis for viral maturation and propagation, leading to drug 
resistance. 
The study of drug-resistant protease mutations has been critical to HIV therapy 
involving application of PIs. Some protease mutations directly change interactions 
between the protease and its inhibitors. For example, mutations in the protease 
substrate cleft, e.g., at D30, V82 and I84, tend to cause resistance by reducing the 
binding affinity between the mutant protease and inhibitors. Mutations at M46, I47, 
G48, I50 and I54 in protease affect its dynamic properties and influence its ability to 
bind with substrate and inhibitors. Mutations elsewhere in the enzyme either 
compensate for its decreased kinetics due to active-site mutations or also cause 
resistance by altering inhibitor-binding kinetics, or by reshaping the active site 
d
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through long-range st mutations reduce the 
in vitro susceptibility to one or more PIs by 2- to 5-fold. However, additional 
mutat
on mutation at position 82 (V82A/V82T is 7/1).4 The I84V mutation, 
which
ructural perturbations. Most substrate-cleft 
ions are usually required in the enzyme flap and in other parts of the molecule 
for the emergence of in vivo resistance. 
V82A/T mutations occur predominantly in HIV-1 isolates from patients 
receiving treatment with indinavir or ritonavir.2,3 V82A also occurs in isolates from 
patients receiving prolonged saquinavir therapy following development of the 
mutation G48V. By themselves, mutations at codon 82 confer reduced susceptibility 
in vitro to indinavir, ritonavir, and lopinavir, but not to nelfinavir, saquinavir, or 
amprenavir. However, when present with other PI-induced mutations, the V82A/T 
mutations contribute phenotypic and clinical resistance to each of the PIs. V82A is the 
most comm
 has been reported in patients receiving indinavir, ritonavir, saquinavir, and 
amprenavir as their sole PI,2,3 causes phenotypic and/or clinical resistance to each PI. 
The G48V mutation occurs primarily in patients receiving saquinavir and rarely in 
patients receiving indinavir. 5 This mutation causes 10-fold resistance to saquinavir 
and about 3-fold resistance to indinavir, ritonavir, and nelfinavir. G48V has been 
reported to cause low-level biochemical resistance to amprenavir when present in 
site-directed mutants, but to interfere with amprenavir resistance when present with 
more typical amprenavir-resistant mutations such as M46I, I47V, and I50V.5 Its effect 
on lopinavir and atazanavir is not known. G48V usually occurs with mutations at 
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positions 54 and 82.6 The protease flaps (residues 33-62, which consist of a short 
anti-parallel β-sheet with a turn, extend over the substrate-binding cleft and must be 
flexible to allow entry and exit of the polypeptide substrates and products.7 The flap 
tips (residues 46-54) are particularly mobile and are the site of many drug-resistant 
mutations. In addition to mutations at positions 48 and 50, which extend into the 
substrate cleft, mutations at positions 46, 47, 53, and 54 make important contributions 
to drug resistance. Mutations at position 54 (generally I54V, less commonly 
I54T/L/M/S) contribute resistance to each of the approved PIs.2 I54L and I54M are 
particularly common in persons receiving amprenavir and have a greater effect on 
amprenavir than does I54V.8  
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Thermodynamics of protease-inhibitor binding 
 
To elucidate the mechanisms of these drug-resistant mutations of HIV protease, 
over 200 crystal structures of HIV-1 protease variants have been solved. Changes in 
affinity due to drug-resistant mutations and thus the thermodynamics of binding can 
be measured by ITC (isothermal titration calorimetry). Comparison of the structures 
of wild-type and drug-resistant variant protease in complex with inhibitors partially 
rationalizes how specific protease mutations decrease protease-inhibitor binding 
affinity. However, it is still a challenge to illuminate critical changes in binding 
affinity in a quantitative way from the structural data. Free-energy simulations, in 
principle, can aid in elucidating these components of the binding affinities to 
particular atomic interactions. Among all the methodologies of free energy prediction, 
free-energy perturbation4,9-11 and MM-PB/GBSA methods have been broadly applied 
to a wide range of biomolecular systems to study protein-protein, protein-DNA/RNA, 
and protein-ligand interactions. 
 
Thermodynamic integration method 
The thermodynamic integration (TI) method is a free energy perturbation 
method that is mostly employed to study relative binding free energy changes. If one 
takes the derivative of the equation QlnNVTG RT   with respect to , where the 
Hamiltonian H has been replaced by the -dependent potential function V ( , x), one 
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obtains: 
dG RT dQ
d Q d 
            
By reference to the partition function defined as  
 
NVT
 
exp( ( , ) / )Q C dxdp H x p RT   , differentiation and substitution leads to  
   
 
 
, /
, /
, V x RT
V x RT
dV x
e dx

,d dV xdG
d de dx 

 


    

. 
 
Integration gives:     
 

1
0
G d
d
( , )dV x

     
 
This is the master equation for the free energy method known as TI. In the master 
quation equation, ΔG refers to the change in free energy, the integrand is evaluated at 
ral is approximated from these points using a 
numer
e
a series of discrete points and the integ
ical integration method. For example, the simple trapezoidal integration method 
is frequently used. When this method is applied to the previous equation, one gets 
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 
 
 
 
 N 1
1 i i 1
V x, V x, i 1 (i)
G
2 
  
 


              

 

 
For TI, the main concern with respect to the   pathway is that enough   
points are selected so that the numerical integration over these points is reasonably 
accurate. To obtain ΔG versus   curves that vary s oothly and slowly, a m
ber of points will usually suffice. Fortunately, such a curve is characteristic of 
most free energy calculations. 
 
MM-PB/GBSA method 
The MM-PB/GBSA method combines molecular mechanics and the 
 the binding free energy of biomolecular 
interactions.12 MM refers to molecular mechanics, PB refers to the 
oisson-Boltzmann equations, GB refers to the general Born model which 
m odest 
num
continuum solvation model to calculate
P
approximates the PB model, and SA refers to the solvent-accessible surface area.  
In applying the MM-PB/GBSA model to calculating the binding affinity 
between the protease and inhibitor, the binding free energy change ΔGbinding in the 
process:  
 
is represented by equation 1: 
G                (1) /binding MM PB GB NPG G T S G        
 18
ΔGMM is the molecular mechanics energy change, here described and calculated by 
the AMBER force field functions and parameters as in equation 2:  
MM bond angle dihedral vdw eleG G G G G G               (2) 
 of protease-inhibitor binding. 
In equation 1, the entropy was calculated by normal-mode analysis using the 
ule. 
The bond stretching energy change (ΔGbond), angle vibrational energy change 
(ΔGangle), and dihedral angle torsion energy change (ΔGdihedral) are the bonded energy 
change terms. The van der Waals interaction energy change (ΔGvdW) and electrostatic 
interaction energy change (ΔGele) are the non-bonded energy change terms, which are 
of specific interest in my study
AMBER 8 NMODE mod
translational rotational vibrationalS S S S        
lnln
v
Qs k Q
   
 Bk T 
3/ 2( / 2 )trans B
Q
h k T m  
V
1/ 23/ 21/ 2 1 1Q    rotational hck T I I I
   
B A B C  
     
The polar component of the solvation free energy change, represented by 
ΔGPB/GB is calculated as: 
For each species (protease, inhibitor, and complex), the polar solvation 
changes are calculated by the PB or GB method. In the PB method, the electrostatic 
 
Protease Inhibitor Complex
PB/ GB PB/ GB PB/ GB PB/ GBG G G G       
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potential produced by a molecular charge distribution is determined by solving the 
Poisson-Boltzmann equation. 
The Poisson function 
   
0
r
r
    
 E r (r)   
defines the relation between the electrostatic potential φ(r), electrostatic field E(r), and 
the charge density ρ(r). The charge density is not isotropic because interactions 
between ions create the atomic atmosphere. To account for this effect, the 
Debye-Huckel theory employs the Boltzmann factor of dissolved ions in the local 
electrostatic potential (   ir qe 
centr
) to estimate changes in the local ion concentration C(r) 
relative to their bulk con ation : 0iC
    ir q0iC r C e   
In a system where the electrolyte has N types of ions with charge qi and concentration 
Ci., the Poisson-Boltzmann equation is: 
This analytical approach was first developed by Kirkwood13 and later revised 
to the Tanford-Kirkwood model.14 In this approach, biomolecules are considered as 
symmetric geometric bodies to allow the analytical solution of the PB equation. With 
increases in asymmetry, it becomes more difficult to solve the equation analytically. 
One must then resort to numerical methods.  
        iN r q0i i
i 1
r r r q C e    

        
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One numerical approach that has achieved great success in the study of 
electrostatic interactions among biomolecules is the Finite Difference Solution to the 
PB equation (FDPB) method.15-18 A typical FDPB process19 includes the following 
steps: assigning atomic changes to the finite difference grid points, determining 
electrostatic potentials on the boundary surfaces of the finite difference grid, and 
introducing a dielectric model to define the boundary between a high dielectric region 
(usually water) and low dielectric region (biomolecule interior). Then the partial 
differential equation can be converted to a linear system and the numerical solution of 
the PB equation is calculated to convergence. 
In the GB method, the generalized Born equation is used to calculate the polar 
solvation energy change. The electrostatic free energy of a system comprising 
particles with radii  and charge in a solution with dielectric constant ε can be 
represented as: 
iL iq  
2N N N
i j i
ele
i j
G 1 
iij i
q q q1 1
r 2 L 
      
where is the distance between atom i and atom j. The electrostatic free energy 
difference between the system in vacuo and in solution can be calculated by the 
generalized Born equation:   
ijr  
2N N N
i j i
ele
i j iij i
G 1 1
r 2 L            
q q q1 1 1      
The GB equation can be expressed in one term20 
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where Ri is the effective Born radius of atom i, which reflects the degree of its burial 
inside the low dielectric region defined by the solvent boundary. In the OBC 
(Onuvriev, Bashfod and Case) GB method21, Ri was modified to be suitable for 
macromolecules.   
The nonpolar contribution of the solvation free energy change is represented 
by ΔGNP, which is linearly dependent on the solvent-accessible surface area A: 
ΔGNP=
le
ce area. The surface area can be calculated by Sanner’s MSMS 
software23 using a water-sized probe. The MM-PB/GBSA method has been widely 
used to calculate absolute binding free energy changes associated with biomolecular 
recognition and relative free energies of different conformations.24-28  
 
γA+b.22 This dependence is due to ΔGNP being mainly determined by 
interactions between the solute and solvent molecules in the first solvation shell, 
where the number of solvent mo cules is approximately proportional to the 
accessible surfa
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Protease dynamics 
 
Protein dynamics, structure, and function are highly correlated. In the case of 
ge is highly related to the flexibility of the flap region and 
hydrop
tail about the 
dynamic properties in a single molecule. One of the principal tools in the theoretical 
study of biological molecules is the method of MD simulation. This computational 
method calculates the time-dependent behavior of a molecular system. It is a 
deterministic method, which means that the state of the system at any future time can 
be predicted from its current state. MD simulations provide detailed information on 
HIV protease, the dynamics of conformational changes are extremely critical for 
enzyme function. The first step in the HIV-1 protease substrate-cleavage reaction is 
opening of the protease flaps to expose the active site pocket to the substrate. This 
conformational chan
hobic core movements of the protease.29 The motions of the flap tips in 
unbound HIV-1 protease have been investigated using nuclear magnetic resonance 
(NMR)30,31 and molecular dynamics (MD) simulations.29 These studies indicate that 
the flaps are highly mobile and can adopt a large number of conformations on the 
nanosecond to microsecond timescale, suggesting that mutations in the flaps can be 
very important for the enzyme’s kinetics and inhibitor binding. 
NMR spectroscopy can determine the time scales of atomic fluctuations and 
relative atomic positions of proteins, but the results are based on an ensemble of 
molecules in the solution. Thus, NMR cannot provide enough de
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the fluctuations and conformatio eins and nucleic acids at the 
atomic level. In MD simulation, Newton’s equation of motion 
nal changes of prot
VF ma
r
  
    
is solved for a given potential ( )V r , to represent a protein and its environment, 
where the potential of this system is described by a force field function: 
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Sets of atomic positions are derived in sequence by applying Newton’s 
equation. The displacement of each atom ( ( )ir t
 ) is integrated by breaking the 
calculation into a series of very short time steps, typically between 1 and 10 
femtoseconds. At each step, the forces on the atoms are computed and combined with 
their current positions and velocities to generate new positions and velocities a short 
time ahead. The force acting on each atom is assumed constant during the time 
interval. The atoms are then moved to their new positions, an updated set of forces is 
computed, and the process is repeated. In this way a molecular dynamics simulation 
generates a trajectory that describes how the dynamic variables change with time. MD 
simulations are typically run for several to a hundred nanoseconds. The MD method is 
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now routinely used to investigate the structure, dynamics, and thermodynamics of 
biological molecules and their complexes. 
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Summary 
 
The scope of this thesis is to use computational methods to investigate the 
mechanism of HIV-1 protease drug resistance on an atomic level. Free energy 
simulation methods were used to calculate the free energy change of 
protease-inhibitor binding and the results were compared with ITC experimental data. 
Free energy decomposition analysis was performed on the binding of drug resistant 
variants and WT with inhibitors to find out the major reason of binding affinity loss. 
Molecular dynamic simulation of proteases was performed to compare the difference 
in dynamic properties between WT and drug resistant variants. Improved 
understanding of the thermodynamic and dynamic properties of the protease variants 
will contribute to rational design of new protease inhibitors which bind more tightly 
to the protease and hinder the development of drug-resistant mutations. 
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Chapter II  
Decomposing the energetic impact of 
drug resistant mutations in HIV-1 
protease on binding DRV
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Abstract 
Darunavir (DRV) is a high affinity (Kd=4.5X10-12M, ΔG=-15.2 kcal/mol) HIV-1 
protease inhibitor. Two drug-resistant protease variants, FLAP+ (L10I, G48V, I54V, 
V82A) and ACT (V82T, I84V), decrease the binding affinity of DRV by 1.0 kcal/mol 
and 1.5 kcal/mol respectively. In this study, the absolute and relative binding free 
energies of DRV with wild-ty d CT were calculated with 
MM-PB/GBSA and thermodynamic integration methods, respectively. Free energy 
dec ve 
site of ited 
to the sites of ane moiety of 
DRV maintains interactions with the FLAP+ and ACT variants, whereas the 
4–aminophenyl group is more flexible in the FLAP+ and ACT complexes than in the 
wild-type protease which could account for the majority of the loss in binding free 
energy. This suggests that replacement of the 4–aminophenyl group may generate 
new inhibitors less susceptible to the drug resistant mutations. 
pe protease, FLAP+ an  A
omposition elucidates that the mutations confer resistance by distorting the acti
 HIV-1 protease so that the residues that lose binding free energy are not lim
mutation. Specifically, the bis-tetrahydrofuranylureth
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Introduction 
 
The human immunodeficiency virus type 1 (HIV-1) protease is a homodimeric 
aspartyl enzyme with 99 residues in each chain. The two HIV-1 monomers are bound 
by non-bonded interactions, with the active site at the interface between the two 
monomers.  The protease processes the viral Gag-Pol polyprotein, yielding the 
structural proteins and enzymes critical for the maturation of infectious viral 
particles.  Thus, HIV-1 protease has been a major target for structure-based drug 
design. Nine protease inhibitors have been approved by the Food and Drug 
Administration (FDA) for HIV therapy, effectively decreasing the mortality rate of 
HIV/AIDS patients. These FDA-approved HIV-1 protease inhibitors, were developed 
at least in part, using structure based drug design, are competitive inhibitors.  
Unfortunately, exposure to protease inhibitors leads to the virus developing drug 
resistance mutations in the protease due to the high replication rate of HIV-1 and to 
lack of a proofreading mechanism in its reverse transcriptase. These drug-resistant 
protease variants lose their high binding affinity to the inhibitors, while maintaining 
enough enzyme activity for the virus to propagate.34 
To understand the basis for these changes in drug-resistant proteases, over 200 
crystal structures of HIV-1 protease variants have been solved in the past 25 years. 
Changes in affinity due to drug resistant mutations and thus the thermodynamics of 
binding can be measured by isothermal titration calorimetry.35,36 Comparison between 
32
33
33
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the structures of wild-type and dru riant proteases in complex with 
inhibitors partially elucidates how specific protease mutations decrease 
pr
inding free energy of inhibitors 
w
g-resistant va
otease-inhibitor binding affinity.37,38 However, elucidating the critical components 
of the binding affinity quantitatively from the structural data still remains a challenge. 
Free-energy simulations39-44, in principle, can aid in elucidating these components of 
the binding affinities to particular atomic interactions.  
Among these computational methods, free-energy perturbation (FEP) and 
thermodynamic integration (TI) methods, which are derived from statistical 
mechanics11,42,45-48, are mostly used with the thermodynamic cycle to calculate 
relative binding free energy changes in similar systems. The Molecular-mechanics 
Poisson-Boltzmann surface area (MM-PBSA) method combines molecular mechanics 
and the continuum solvation model.12,43,49-51 Solvation properties can be described by 
the Poisson-Boltzmann (PB) or generalized Born (GB) equation. This method is 
reliable and applicable to calculate absolute binding free energy change associated 
with biomolecular recognition. To achieve a better match with experimental data, 
MM-PB/GBSA method is usually supplemented by entropy estimation. Free-energy 
calculation methods provide a way to estimate the b
ith different protease variants, allowing computational screening of lead compounds 
in rational drug design. Furthermore, the calculation results can be further analyzed, 
e.g., for free energy decomposition, to provide information about affinity changes due 
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to specific kinds of interactions on an atomic level, which can not be determined by 
experimental methods.12,43,52,53  
The HIV-1 protease inhibitor, Darunavir (DRV, formerly known as TMC114) 
(Figure 2.1A) has recently been approved by the FDA.54 This second-generation 
protease inhibitor, which was developed after extensive effort in rational drug 
design55, has the lowest dissociation constant of all reported HIV protease inhibitors 
(K
mechanism for resistance of FLAP+ and ACT to DRV. The free energy 
d =4.5X10-12M).35 Nonetheless, DRV still loses affinity to drug resistant variants of 
HIV-1 protease35.  In this study, the binding of DRV was investigated with wild-type 
HIV-1 protease and two drug-resistant variants: FLAP+ (Figure 2.1B) with L10I, 
G48V, I54V, V82A which are a combination of flap and active site mutations, and 
ACT (Figure 2.1C) with V82T, I84V which are active site mutations. Each of these 
three systems was analyzed in three parallel 20 ns molecular dynamics (MD) 
simulations using initial coordinates from their crystal structures. In these MD 
simulation trajectories, the MM/PBSA and MM/GBSA methods were applied to 
calculate changes in binding free energy, which were compared with ITC results. The 
classical TI method was also used to calculate and compare differences in binding 
free energy of the DRV-ACT and DRV-WT complexes. The accuracy, convergence 
and reproducibility of the calculated results have been compared and discussed. The 
MM-PB/GBSA and TI calculation results are in good agreement with the 
experimental data. Free energy component analysis was performed to elucidate the 
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decomposition study results show that the bis-THF group of DRV maintains its 
favorable van der Waals (vdW) contact with the protease even in the drug resistant 
va
Bis-THF: bis-tetrahydrofuranyl 
ITC: isothermal titration calorimetry  
GB: generalized Born  
FLAP+: HIV-1 protease variant L10I, G48V, I54V, V82A 
riants. Understanding how the protease mutates to decrease its binding affinity with 
a very high affinity inhibitor will contribute to developing better strategies to design 
protease inhibitors. 
 
Abbreviations: 
TI: thermodynamic integration 
MM/PBSA: molecular mechanics/Poisson-Boltzmann surface area 
DRV: Darunavir 
ACT: HIV-1 protease variant V82T, I84V 
vdW:  Van der Waals 
MD:  Molecular Dynamics 
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ns: nanosecond 
ps: picosecond 
fs: femtosecond 
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Figure 2.1: (A) Chemical structure of DRV. (B) Structure of protease variant 
colored yellow. The side chains of the mutated 
residues Ile10, Val48, Val54, and Ala82 are displayed and colored red or green. (C) 
Structure of protease variant ACT-DRV complex. DRV is colored yellow. The 
side chains of the mutated residues Thr82 and Val84 are displayed and colored 
red or green. 
FLAP+-DRV complex, DRV is 
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Methods 
 
MD simulation with the program Sander in the AMBER 8 package  
The initial coordinates of the DRV-WT protease complex are taken from its crystal 
structure 1T3R.35 Similarly, the DRV-FLAP+ protease complex coordinates are from 
its crystal structure 3EKT and the DRV-ACT protease complex coordinates are from 
its crystal structure 1T7I.35  
Molecular dynamics simulations were performed using the program Sander in the 
MD simulation package AMBER 8.56 For the standard protease residues, the atomic 
partial charges, van der Waals parameters, equilibrium bond lengths, bond angles, 
dihedral angles, and their relative force constants were taken from the AMBER 
database (ff03).57 For DRV parameters, the van der Waals parameters, equilibrium 
bond lengths, bond angles, dihedral angles, and force constants were taken from the 
General AMBER Force Field database.58 The partial charges of inhibitor atoms were 
obtained as follows. First, the coordinates of the DRV atoms were taken from the 
1T3R crystal structure, and the missing hydrogen atoms added by the program Quanta. 
Second, the geometry of the resulting structure was optimized with the (HF)/6-31G* 
basis set by Gaussian 03 package.59 Finally, the resulting electrostatic potential was 
used in the RESP60 module of the AMBER 8 package to derive the atomic partial 
charges of the inhibitor. 
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The explicit solvent model was applied to all systems. Each structure was solvated 
with the TIP3P water cubic box to allow for  
 dimensions 
of
ization process with the steepest descent method was 
us
NPT ensemble without restraining heavy atoms. In the 
subsequent sampling MD simulations, each step was 2fs, and the total simulation was 
 at least 8 Å of solvent on each face of the
protease. The vdW dimensions for the protease are 44 by 35 by 59 Å. The
 the final periodic box are 63 by 55 by 78 Å. The simulation system had 
approximately 7000 water molecules, and six Cl- counterions were added to balance 
the charge of the system.  
A three-step energy minim
ed to allow the system to reach an energetically favorable conformation. In the first 
energy minimization step, all the heavy atoms of the protease were restrained with a 
harmonic force constant of 10 kcal mol-1Å-2. In the second step, only the backbone 
nitrogen, oxygen, and carbon atoms were restrained. In the third step, all atoms were 
allowed to move. Each of the three steps had 2000 cycles. The temperature of the 
energy-minimized system was then gradually raised from 50ºK to 300ºK in the NVT 
ensemble. Initial velocities were assigned according to the Maxwellian distribution, 
and random seeds were assigned with three different values to generate nine 
simulations, three parallel simulations for each of the WT-DRV, FLAP+-DRV, and 
ACT-DRV systems. In the thermalization process, heavy atoms were restrained with a 
harmonic force constant of 10 kcal mol-1 Å-2. The whole process was 50 picoseconds 
(50,000 steps, each of which was 1 femtosecond). A 50 picoseconds equilibration was 
then performed in the 
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20 ns. For the thermalization, equilibration, and sampling simulations, the SHAKE 
algorithm61 was applied to constrain all hydrogen atoms.  
 
MM-PB/GBSA method  
For the protease–ligand system, the binding free energy change is represented by:  
 
and 
G
where  
/binding MM PB GB NPG G T S G          
MM bond angle dihedral vdw ele
translational rotational vibrational
G G G G G          G
 
 
The molecular mechanical energy ΔGMM is the estimated free energy change 
associated with the binding process in gas phase. ΔGMM is calculated by standard 
force field functions and parameters. Depending on the type of interaction, ΔGMM has 
two kinds of energetic terms: bonded and non-bonded. The bonded term includes 
terms representing bond stretching energy (ΔGbond), angle vibrational energy (ΔGangle), 
and dihedral angle torsion energy (ΔGdihedral). The non-bonded term includes terms 
S S S S        
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representing the van der Waals interaction energy (ΔGvdW) and electrostatic 
interaction energy (ΔGele)  
The polar component of the solvation free energy, represented by ΔGPB/GB, can be 
ann equation (PB method) or the 
ge  
free energy is represented by ΔGNP. The sum of ΔGPB/GB and ΔGNP estimates the free 
energy change associated with molecules entering solvation from the gas phase. The 
GB calculation was done using the model developed by Onufriev et al.62,63 The PB 
calculation was done with the AMBER 8 numerical PB solver.19 The solute dielectric 
constant was 1.0, and solvent dielectric constant was 80.0. ΔGNP was calculated by the 
LCPO (linear combinations of pairwise overlaps) method, which is linearly dependent 
on the solvent access surface area: ΔGNP=0.0072 X SASA.22 The entropy was 
calculated by normal-mode analysis using the AMBER 8 NMODE module. For every 
20ps of the 20 ns MD simulation trajectory, a snapshot of the protease and inhibitor 
was taken removing the solvent and counter ions. Total number of the atoms for each 
of the three systems: DRV-WT, DRV-FLAP+, DRV-ACT are 3203, 3209, 3203 
respectively. Altogether, 1000 frames were used for the MM-PB/GBSA calculations. 
 
Thermodynamic integration method  
When studying drug-resistant protease mutants, the binding free energy relative to 
wild-type protease is even more important than the absolute binding free energy. 
calculated either by solving the Poisson-Boltzm
neralized Born equation (GB method). The nonpolar component of the solvation
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lnG RT Q 
atistical mechanics, the Gibbs free energy (G) can be calculated from the partition 
function Q as follows:  
                                                                    
(1) 
The partition function can be expressed as the integral of the system’s Hamiltonian 
function H(r,p). After introduced a coupling parameter, lambda, into the Hamiltonian, 
Q can be expressed as:  
 
 
                                                                     
(2) 
 
From equation (1) and (2), the derivative of G with respect to lambda is:  
 
 
exp( ( , , ) /Q drdp H r p    )RT
ifference between different states of the system. From 
st
           
           
                                         
Thermodynamic integration method4,64 was applied to the protease-inhibitor system to 
compute the free-energy d
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and 
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ying this equation to the protein–ligand system, the kinetic component of the 
H
tion V(0) and its relative parameters are correlated with the 
wild-type protease. When λ=1, V(1) and its parameters are correlated with the mutant 
protease. The numerical estimation of equation 4 is:  
  (5) 
 
quadratic formula.  
Directly calculating thermodynamic integration from the unbound to the bound 
state is not feasible. The thermodynamic cycle b
 function and is independent of the path.  
                                                                                          
 
                                                                    
(4)   
 
Equation 4 is the master equation of the thermodynamic integration method. When 
appl
amiltonian can be neglected. Thus, the lambda-coupling force field function V (λ, r) 
is used to replace the Hamiltonian. The lambda is chosen such that when it equals 
zero, the force field func
The lambda values and their relative weights were assigned from the Gaussian 
 
elow is used since G represents a 
state
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2 1 4G G G G       3G
As shown above, instead of calculating the free energy changes ΔG1 and ΔG2 
associated with the chemical reaction path, the ΔG3 and ΔG4 through the “alchemical” 
path 65,66 are calculated. 
Thus, the drug-resistant mutant’s loss of binding free energy compared to the 
wild-type protease is represented by: 
                                                                                             
(6) 
The thermodynamic integrations were carried out in the Sander module of the 
AMBER 8 package.67,68 The wild-type and mutant proteases have different numbers 
of side chain atoms on the mutated residues. To keep the same number of atoms in the 
initial and final states, I perturbed the extra atoms to dummy atoms, which had no 
nonbonding interactions with the rest of the system. When carrying out 
thermodynamic integration calculations, the Sander module in AMBER 8 only 
allowed dummy atoms to appear in the perturbed Hamiltonian.67,68 It was not feasible 
for Sander to perform the thermodynamic integration calculations for the FLAP+ 
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mutant (L10I, G48V, I54V and V82A), since Leu10 in the WT and Ile10 in the 
FLAP+ mutant have the same number of side-chain atoms but different tree structures, 
Gly48 has fewer atoms than Val48, and Ile54 and Val82 in the WT have more atoms 
than Val54 and Ala82 in FLAP+. For the ACT mutant, both mutated residues (V82T, 
I84V) have fewer atoms than the wild type. Thus the perturbation is done from WT to 
ACT. (Figure 2.2) 
The DRV-WT crystal structure 1T3R was used to generate the perturbed topology 
file and the coordinates file for the calculation of the ΔG4. For the calculation of ΔG3, 
two sets of topology and coordinates files were created. One is from the unbound 
wildtype protease crystal structure 1HHP and one is the protease atoms coordinates 
extracted from the WT-DRV complex crystal structure 1T3R. The three steps energy 
minimization was performed as described before. The structure was then thermalized 
and pre-equilibrated with a harmonic restrained force and the lambda value was 0.5. 
During the thermalization, different random seed values were assigned to create 
parallel calculations as control. The pre-equilibrated structure was then started to 
sampling at 12 lambda values. The time steps were 1fs and the time for the calculation 
at each lambda values was 2 ns. Thus the total sampling time for each alchemical free 
energy change calculation is 24 ns. The expected error in the free energy calculations 
is the root mean square deviation in the energies of the sample in production period 
divided by the square root of the number of independent samples in the production 
period.68,69  
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  (7) sample-rmsexpected-error=
number of independent samples
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Figure 2.2: Perturbation of Val82 to Thr and Ile84 to Val. Hydrogen atoms are 
colored white, oxygen atoms are colored red, nitrogen atoms are colored blue, 
carbon atoms are colored green and dummy atoms are colored black. Left: 
residue in the wild-type protease as the initial state; Middle: the hybrid residue 
in the calculation process; Right: the mutated residue as end state. (A) The 
perturbation of Val82 to Thr82. (B) The perturbation of Ile84 to Val84. 
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Results and Discussion 
 
omparison between predicted binding affinity and ITC data 
alculations of absolute binding free energy by MM/PBSA and MM/GBSA 
ethods 
To evaluate the reproducibility and convergence of our free-energy calculation 
results, the same MM/GBSA protocol was applied to three independent 20 ns MD 
simulation runs of each of the WT-DRV, FLAP+-DRV and ACT-DRV systems 
starting from each of their corresponding crystal structure (see Methods). To study the 
structural stability of the systems, the root mean square displacement (RMSD) of the 
Cα atoms of the simulated proteins were plotted over time with respect to their 
corresponding crystal structures. (Figure 2.3) For all the DRV-protease systems after 
2 ns of MD simulations the RMSD values are approximately 1.5 Å. As the 
calculations all require extensive equilibration, the averages of potential production 
periods were evaluated. After 10 ns simulations the calculated binding free energy for 
DRV-WT stabilizes (Figure 2.4) for all three parallel s ach of the 
triplicates of DRV-FLAP+ and DRV-ACT stabilize within 6 and 9 ns respectively 
(Figure 2.4). Thus the first 10 ns is used as the equilibration period, as the free energy 
C
C
m
imulations. E
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generally does not converge between the runs (Table 2.1), while the second 10 ns is 
used as the production period, since generally the runs are converged.  
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Figure 2.3: RMSD of Cα atoms of protease with respect to their corresponding 
crystal structures during the 20 ns MD simulations. (A) RMSD of Cα atoms of 
DRV-WT simulations. (B) RMSD of Cα atoms of DRV-Flap+ simulations. (C) 
RMSD of Cα atoms of DRV-ACT simulations. 
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(C) 
 
 
 50
Figure 2.4: MM/GBSA calculated results of DRV-protease binding free energy 
with respect to the time. The three curves represent calculation results based on 
the three independent MD trajectories. (A) DRV-WT (B) DRV-FLAP+ (C) 
DRV-ACT  
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Table 2.1: Results of MM/GBSA Calculation for Absolute Binding Free Energy 
(kcal/mol) of DRV-Protease Based on Equilibration (1-10 ns) and Production 
(11-20 ns) Periods. 
Protease Sampling time (ns) Run 1 Run 2 Run 3 Average 
1-10 -33.4  -32.8  -24.9  -30.4 
WT 
11-20 -27.3  -27.0  -25.7  -26.7 
1-10 -23.4  -17.7  -20.1  -20.4 
Flap+ 
11-20 -21.1  -20.8  -21.1 -21.0 
1-10 -20.3  -13.9  -25.5  -19.9 
ACT 
11-20 -17.8 -17.6  -19.8  -18.4 
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The average predicted binding free energy of WT-DRV is -26.7 kcal/mol, 
FLAP+-DRV is -21.0 kcal/mol, and ACT-DRV is -18.4 kcal/mol (Table 2.1). 
Although these values for each system deviate from the ITC experimental values 
(-15.2 kcal/mol for WT-DRV, -14.2 kcal/mol for FLAP+-DRV, and -13.6 kcal/mol 
for ACT-DRV), they rank in the correct order for the three protease variants’ binding 
free energy: WT > FLAP+ > ACT. The more rigorous and time-consuming PB 
method was also tried to calculate the polar solvation free energy. With this method, 
the predicted results were in better agreement with the ITC experimental data: -15.1 
kcal/mol for WT-DRV, -11.6 kcal/mol for FLAP+-DRV, -10.5 kcal/mol for 
ACT mparison of the predicted polar solvation free energy 
difference calculated using the GB and PB models shows that the GB model has 
underestimated the polar solvation free energy of all three systems. This difference in 
estimates of polar solvation free energy by the GB and PB models has been reported 
and discussed in several studies involving different protein-ligand systems.70-73 Such 
bias did not affect the ranking of binding energies for a given receptor with different 
ligands or for receptor variants with a specific ligand. Consistent with other groups71, 
the MM/GBSA and MM/PBSA methods provided the same rank order of binding 
energies although the absolute values were different, for complexes of HIV-1 protease 
with DRV. (Table 2.2)  
 
-DRV (Table 2.2). Co
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Table 2.2: Binding free energy change calculated by the MM/GBSA and 
MM/PBSA methods (kcal/mol) 
Protease ΔGCAL-GB ΔGCAL-PB ΔGEXP* 
WT -26.71.8 -15.11.8  -15.2  0.8 
FLAP+ -21.01.5 -11.61.5  -14.2  0.6 
ACT -18.41.7 -10.51.7  -13.6  0.1 
 
*Experimental binding free energy data were obtained by ITC (King et al. 2004) 
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Calculation of relative binding free energy  
For the ACT double mutant V82I, I84V, I also calculated relative binding free 
energy by the oro mputationally more intensive thermodynamic 
integration meth his m s prov  po l for studying 
binding free ene eren ceptor- m l mechanics is 
its theoretical fr rk.11, ribed odynamic 
tegration calculates the binding free energy change from WT-DRV to ACT-DRV. 
ΔG4, 
which are the sum of 12 weighted dV/dλ values, are plotted versus time for the study 
of calculation convergence (Figure 2.5). For thermodynamic integration calculations, 
their reproducibility and internal consistency were studied by setting up two sets of 
independent simulations. Comparison of the two calculations of ΔG4, which were 
started from the DRV-WT complex crystal structure coordinates, resulted in using the 
first 0.5 ns of each of the 12 lambda as the equilibration period and the second 1.5 ns 
of each of the 12 lambda as the production period. Total time for the equilibration 
period and production period are 6 ns and 18 ns, respectively. The two ΔG4 values are 
-119.3 kcal/mol for run 1 and -119.9 kcal/mol for run 2 (Table 2.3). The ΔG3 values 
calculated from the 1HHP and 1T3R crystal structure coordinates are -121.4 and 
-121.5 kcal/mol, respectively (Table 2.3). The relative binding free energy between 
DRV-WT and DRV-ACT is 1.8 kcal/mol. This result is a better match with the 
experimental relative binding free energy of 1.6 kcal/mol than 4.6 kcal/mol and 8.3 
more rig us and co
od. T ethod ha en to be a werful too
rgy diff ces in a re ligand syste as statistica
amewo 74 As desc in the Methods section, therm
in
The free energy changes associated with the alchemical pathways ΔG3 and 
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kcal/mol, which were calculated from the MM/PBSA and MM/GBSA methods, 
respectively (Table 2.4).   
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Figure 2.5: Thermodynamic integration results over total sampling time shows 
calculations are stable. (A)ΔG4 from two independent calculations of the 
coordinates of DRV-WT crystal structure (1T3R). (B)ΔG3 from two independent 
starting calculations from different starting structures: DRV-WT crystal 
structure is colored magenta, with the inhibitor removed, and the apo protease 
crystal structure (1HHP) is colored cyan. 
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Table 2.3: Thermodynamic Integration Calculation over 12 lamda on the 
Equilibration and Production Periods (kcal/mol) 
ΔG4 ΔG3 
Period ΔΔG* 
-116.1  0.2 -118.1  0.2 -120.7  0.2 -119.9  0.2 3.2  0.4 
1st Run 2nd Run 1HHP 1T3R 
equilibration 
period** 
production 
period** 
-119.3  0.1 -119.9  0.1 -121.4  0.1 -121.5  0.1 1.8  0.2 
 
*:ΔΔG=Mean (ΔG4-ΔG3) 
** Note equilibration period is the first 0.5 ns of each of the 12 lamda and 
production period is the second 1.5 ns of each of the 12 lamda, of the entire
alculation. Total equilibration time is 6 ns and production time is 18 ns. 
 
c
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Table 2.4: Relative Binding free energy (kcal/mol) of ACT and WT HIV-1 
Protease Calculated by Thermodynamic Integration, MM/GBSA and MM/PBSA 
Methods vs ITC Data  
  
Ther ic
integration 
MM/GBSA MM/PBSA ITC 
modynam
ΔΔG 1.8  8.3  4.6  1.6  
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Free-energy decomposition analysis  
Analysis of contributions from different energy components  
Free energy component analysis is performed to elucidate the mechanism for 
resistance to DRV of FLAP+ and ACT. The different energy components in the 
MM-PB/GBSA model (see Methods) are shown in Figure 2.6 and tabulated in Table 
2.5 in  detail. Bo nslational e  (-TΔStransl change and ional 
ntropy change (-TΔSrotational) are close in value for DRV binding in the three protease 
variants. They represent at least 90% of the change in entropy. The remaining 
vibration entropy change (-TΔSvibrational) is 1.5 kcal/mol for DRV-WT binding, 2.2 
kcal/mol for DRV-Flap+ and 0.2 kcal/mol for DRV-ACT. Further free-energy 
component analysis reveals that the favorable electrostatic interaction energy term 
(ΔGELE) from the molecular mechanical energy (ΔGMM) has been canceled by the 
unfavorable polar solvation energy (ΔGGB) penalty. This result is in agreement with 
other MM-PB/GBSA studies.50,75-78. The total electrostatic interaction energy 
(ΔGELE+ ΔGGB) for DRV-WT is 15.4 kcal/mol, for DRV-FLAP+ is 14.1 kcal/mol, 
and for DRV-ACT is 17.0 kcal/mol. The vdW interaction energy is -60.3 kcal/mol for 
DRV-WT, -54.5 kcal/mol for DRV-FLAP+, and -52.8 kcal/mol for DRV-ACT. vdW 
interactions have the largest contribution to protease-inhibitor binding (Figure 2.6A) 
and sustain the largest energy loss in both the FLAP+ and ACT drug-resistant mutants 
(Figure 2.6B). 
 more th tra ntropy ational)  rotat
e
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Figure 2.6: (A) Binding free energy components of DRV-WT, DRV-FLAP+ and 
th DRV of FLAP+ 
an
DRV-ACT. (B) The loss of binding free energy components wi
d ACT compared to the WT protease.  
(A) 
 
 
(B) 
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Table 2.5. Binding Free Energy Components (kcal/mol) of DRV with WT, FLAP+, 
and ACT Protease  
Protease ΔGvdW ΔGELE ΔGGB ΔGSA -TΔStran -TΔSrot -TΔSvib ΔGPB 
 
WT 
-60.3 -37.4 52.8 -8.1
±0.2 ±0.2 ±0.2 
 
±0.0 
13.4 
±0.0 
11.4 
±0.0 
1.5 
±1.8 
64.4 
±0.4 
FLAP+ 
-54.5 
±0.1 
-39.8 
±0.2 
53.9 
±0.2 
-7.6 
±0.0 
13.3 
±0.0 
11.5 
±0.0 
2.2 
±1.5 
63.3 
±0.3 
ACT 
-52.8 
±0.2 
-35.3 
±0.2 
52.3 
±0.2 
-7.6 
±0.0 
13.3 
±0.0 
11.5 
±0.0 
0.2 
±1.7 
60.2 
±0.4 
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Free energy projected to each residue of HIV-1 protease  
In order to gain extra insight into the mechanisms of protease-inhibitor binding and 
drug resistance, the binding free energy calculated from the MM-GBSA method has 
bee oke n ivi rot resi Th rgy ren as 
investigated en WT  co x a e t rug-resistant nt 
protease-DRV complexes for each residue (Figure 2.7). The residues with energy 
changes wer ly d in  are r , th ytic n ( es 
2 to 33), the flap region (residues 45 to 55), and the P1 loop region (residues 79 to 87) 
on both monomers of the protease. These energy changes vary asymmetrically in the 
two protease monomers. Many residues (G27, A28, I50, R87, K8’, A28’, D29’, I47’, 
L76’) structurally adjacent to DRV other than those that mutate (L10I, G48V, I54V 
and V82A for FLAP+, V82T and I84V for ACT) respond to the mutations (Figure 2.7) 
as has been previously observed 44,53. The sites of mutation not only impact their own 
binding free energy interactions with inhibitors, but also influence the interaction of 
other residues with inhibitor by inducing alterations in the geometry of the binding 
site.  
Favorable electrostatic interactions opposed by the polar solvation energy penalty 
also apply to individual residues. A change in electrostatic energy (ΔΔGELE) of any 
residue is always associated an equal but opposite compensation in solvation energy 
(ΔΔGGB) of very similar amplitude but in a different direction. The correlation 
coefficient for the ΔΔGELE and ΔΔGGB of FLAP+ is -0.94 and for the ACT is -0.91 
n br n dow to ind dual p ease dues. e ene  diffe ce w
 betwe  the -DRV mple nd th wo d muta
e main locate  three as (Figu e 2.8) e catal  regio residu
2
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(Figure 2.9A for FLAP+, Figure 2.9B for ACT). This high correlation of ΔΔGELE and 
ΔΔGGB makes the change of vdW energy the largest factor in the loss of binding free 
energy between DRV and FLAP+/ACT. These residues (in the catalytic, flap, and P1 
loop regions) also have the largest change in vdW interaction energy (Figure 2.10). 
To highlight those residues with a significant difference between the WT and the two 
drug-resistant mutants, a cutoff of 0.05 kcal/mol of vdW energy change was set. The 
residues in FLAP+ and ACT with a loss of vdW energy greater than the cutoff plotted 
in Figure 2.10C. In chain A these residues include T26, G27, A28, I47, G49, and I50; 
in chain B, these residues are K8’, D25’, G27’-T31’, I47’-G49’, G51’, G52’, I54’, 
L76’, V82’, and G86’. (Figure 2.8D). The loss in vdW interaction energy of chain B 
is significantly larger than that of chain A. 
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Figure 2.7: Per residues energy of MM/GBSA calculated results. (A) Energy 
difference between Wild-type protease and FLAP+ variant. (B) Energy 
difference between Wild-type protease and ACT variant. 
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Figure 2.8: (A) Darunavir in the wild-type protease binding site, highlighting the 
flap region(residue 47-54 of both monomers in red), catalytic region(residue 
25-30 in magenta) and P1 loop region(residue 79-84 in cyan). (B&C) Atomic 
details of the protease binding pocket viewed from the front(B) and top(C). (D) 
/M) in the drug resistant variants. 
Residues which have significant lost of vdW interactions energy (larger than 0.2 
kcal
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(A) 
 
(B) 
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Figure 2.9: Correlation between ΔΔGELE and ΔΔGGB of each residue. (A) Energy 
difference between FLAP+ and WT. (B) Energy difference between ACT and 
WT.  
(A) 
 
 
(B) 
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Figure 2.10: (A) Per residues vdW energy loss between FLAP+ and WT protease. 
(B) Per residues vdW energy loss between ACT and WT protease. (C) Residues 
with a vdW energy loss larger than 0.05 kcal/mol. 
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vdW energy contribution from each DRV atom 
To explore the mechanism of binding free energy loss between DRV and the 
drug-resistant mutants, the vdW energy contributions were calculated for each DRV 
atom and compared between complexes with the WT, FLAP+ and ACT mutant 
ases. DRV has 75 atoms, of which 37 are hydrogen atoms with very limited 
contribution to the vdW interaction energy. Thus, data are presented for only the 38 
heavy atoms in DRV (Figure 2.11A). Structurally, DRV can be considered formed by 
four major moieties: A) 4–aminophenyl group, B) isopropyl group, C) benzyl ring, 
and D) bis-tetrahydrofuranylurethane (THF) (Figure 2.11B). To compare the energy 
change between these 4 moieties, I define DV (loss of vdW interaction energy ratio) 
as: 
  
 
 
where i is the atom within a specific moiety. The bis-THF moiety and the benzyl 
ring have relatively low DV of 3.1% and 8.5%, respectively. The 4–aminophenyl and 
isopropyl groups have significantly higher DV of 17.0% and 19.2%, respectively 
(Table 2.6). 
prote
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Figure 2.11: (A s of DRV with 
protease. Energy of DRV-WT is colored dark blue, energy of DRV-FLAP+ is 
colored magenta and energy of DRV-ACT is colored cyan. (B) The definition of 
four moieties of DRV. (C) The chemical structure of APV. 
(A) 
) vdW interaction energy of each heavy atom
 
 
 
(B) 
 
 
 
(C) 
O N
H
N
S
O O
OH
CH3
CH3
OO
NH2
 
 
 75
Table 2.6: Loss of Van der Waals’ Interaction Energy (DV) for Different DRV 
Moieties  
4 – Amino 
Phenyl Group 
bis- 
  Isopropyl Group Benzyl Ring 
Tetrahydrofuranyl
DV (%) 17 19  9  3 
Number of heavy 
atoms 
7 4 7 8 
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 The only difference between DRV and a previous generation protease inhibitor, 
amprenavir (APV) (Figure 2.11C), is that DRV has a second tetrahydrofuran ring, 
which is part of its oiety. Nonetheless, DRV has been shown by ITC 
experiments35 to bin y than APV with the protease, with
larger binding affinity. In the DRV-WT protease structure (1T3R) the bis-THF moiety 
 the protease chain A residues Ala28, Asp29, Asp30, Ile47, Gly48, 
and Gly49, which form a cluster of vdW contacts (Figures 2.12A and 2.12B). This 
packing can be also observed from the crystal structures of the DRV-FLAP+ and 
DRV-ACT complexes35. Examination of the MD simulation structures of DRV in 
complex with the WT, FLAP+ and ACT proteases show that these residues and the 
bis-THF moiety maintain a relatively stable structure compared to other parts of the 
inhibitor. This stability leads to the small ratio of the bis-THF group’s vdW energy 
loss (Table 2.6).  
Similar to the bis-THF group, the benzyl ring maintains its vdW interactions with 
protease residues in chain A (Figure 2.12C) in most conformations sampled by the 
MD simulations. This stability in DRV interactions with chain A explains the 
asymmetric vdW energy losses of the protease’s two chains. Chain B is shown by 
free-energy decomposition of protease residues to have more residues with significant 
energy loss than chain A (Figure 2.9C). Unlike the bis-THF group and the benzyl ring, 
whose vdW interactions were only slightly influenced by the drug-resistant mutations, 
the 4–aminophenyl and isopropyl groups of DRV in complex with FLAP+ and ACT 
bis-THF m
d more tightl  a 2.6 kcal/mol 
is surrounded by
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lo
AP+ and ACT mutant proteases could develop drug resistance. 
st approximately 20% of the vdW interaction energy. Comparison of the MD 
simulation structure of DRV-WT with those of the two drug-resistant mutants shows 
that the 4 – amino phenyl and isopropyl groups of DRV in the DRV-FLAP+ and 
DRV-ACT complexes undergo significant geometry changes (Figure 2.13) that lead 
to these groups losing their vdW contacts with the drug-resistant proteases.  
The free-energy decomposition by residue shows that the mutations have induced 
changes in the shape of the binding pocket as evidenced by the predominant changes 
occurring in the vdW interactions energy. Overall there is a decrease in the vdW 
interaction energy between the protease and DRV, mostly on the 4- amino phenyl side, 
as the volume of the binding pocket is effectively enlarged as the mutations within the 
active site are to smaller residues (V82A in Flap+ and I84V in ACT). Expansion of 
the active site permits, other residues to interact to varying degrees with the inhibitor. 
In this way, the FL
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Figure 2.12: (A) and (B) Cluster of vdW contacts formed by the bis-THF group 
and the protease residues Ala28, Asp29, Asp30, Ile47, Gly48, and Gly49 of chain 
A. The atoms of above residues are displayed and colored green. The atoms of 
bis-THF group are colored red while the remain of DRV is colored blue. (C) 
Relative position of DRV’s four moieties (colored yellow) to Chain A (colored 
cyan) and Chain B (colored purple) of protease. 
(A) 
 
(B) 
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(C)  
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Figure 2.13: (A) Conformational space of DRV sampled in DRV-WT complex simulations. 
Left: DRV ensemble is shown with atoms vdW radii. The original conformation as in the 
crystal structure is colored yellow. The sampled conformations ensemble from MD 
simulation is colored blue. Right: 20 snapshots of DRV conformations taken every 1ns from 
MD simulations. (B) Conformational space of DRV sampled in DRV-FLAP+ complex 
simulations. Left: DRV ensemble is shown with atoms vdW radii. The original conformation 
as in the crystal structure is colored purple. The sampled conformations ensemble from MD 
simulation is colored cyan. Right: 20 snapshots of DRV conformations taken every 1ns from 
MD simulations. (C) Conformational space of DRV sampled in DRV-ACT complex 
simulations. Left: DRV ensemble is shown with atoms vdW radii. The original conformation 
as in the crystal structure is colored orange. The sampled conformations ensemble from MD 
simulation is colored green. Right: 20 snapshots of DRV conformations taken every 1ns from 
MD simulations. 
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Conclusion 
 
With the appearance of drug-resistant HIV-1 protease variants becoming the major 
hallenge to current AIDS therapy, understanding the mechanism of drug resistance is 
ritical. This goal is best addressed by cross-analyzing the data on protease mutants 
om different experimental methods such as crystallography and isothermal titration 
alorimetry. However, more details about inhibitor-protease binding can be provided 
ree energy calculations, which start from structural coordinates and yield 
ermodynamic data. In this study I performed MM-PB/GBSA calculations and 
ee-energy component analysis of DRV-WT, DRV-FLAP+ (L10I, G48V, I54V, 
82A) and DRV-ACT (V82T, I84V). By running three independent 20 ns 
mulations for each of these systems, I not only identified the convergence and 
onsistency of our calculations, but also predicted binding energies in good agreement 
ith ITC data. Moreover, the relative binding free energy between DRV-WT and 
-ACT using MM-PB/GBSA and thermodynamic integration (TI) methods was 
alculated. The accuracy of these result had the rank order 
I>MM/PBSA>MM/GBSA, which is the same order of the computational times 
required for these methods. The TI method is more suitable for comparing the energy 
ifference between two similar systems. In the case of the ACT (V82T, I84V) mutant 
I method not only gav the more accurate predicted energy e 
MM-PB/GBSA method, but also had better reproducibility and faster convergence 
c
c
fr
c
by f
th
fr
V
si
c
w
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c
T
d
here, the T e than th
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(Figure 2.4, Figure 2.5). The free- position analysis indicated that 
mutations in the protease induced confor ational changes in its active site. The 
bi
energy decom
m
s-THF group and benzyl ring of DRV sustain their vdW interactions with the 
drug-resistant protease variants and contribute most to the inhibitor-protease binding, 
while DRV’s 4 – amino phenyl and isopropyl groups are susceptible to changes in the 
protease’s binding pocket and adopt conformations that lose vdW interaction with 
drug-resistant variants. (Table 2.6) 
These findings suggest that the design of new protease inhibitors based on the DRV 
scaffold should consider replacing the 4–aminophenyl and isopropyl groups since 
these regions do not maintain their interactions with drug resistant protease variants as 
much as the bis-THF group. Such new inhibitors would likely bind more tightly to 
HIV protease and may be less susceptible to drug resistance. 
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Chapter III 
 
Molecular dynamics simulation of HIV-1 
protease: Comparison of the dynamic properties 
of WT protease and a drug-resistant variant 
 85
Abstract 
 
HIV-1 protease is an aspartyl enzyme that processes the viral Gag-Pol 
polyprotein, yielding the structural proteins and enzymes necessary for the maturation 
of infectious viral particles. T r with each chain having 99 
residues, 40 of which are hydrophobic. The two monomers bind together by 
nonbonded interactions, and the active site is located at the interface between the two 
monom Drug 
and se 
inhibitors leads to the protease developing drug-resistant mutations. Understanding 
drug-resistant mechanisms on a molecular level is crucial for developing more 
efficient inhibitors. To compare the dynamic properties of the wild-type protease and 
drug-resistant variants, I performed molecular dynamics simulations of the wild-type 
and Flap+ (L10I, G48V, I54V, V82A) variant using the AMBER 8 package. The 
computational analysis shows that this variant has decreased the flexibility in the apo 
form, which might lead to more favorable entropy change upon binding with 
inhibitors compared to the wild-type protease. 
he protease is a homodime
ers. HIV-1 infected individuals are currently treated with 9 Federal 
Administration-approved protease inhibitors. Due to the high HIV-1 replication rate 
 the lack of proofreading ability of its reverse transcriptase, exposure to protea
 86
In  
A
or/substrate, the flap regions in the apo 
protease adopt a “semi-open” status 79-84. However, entrance of the substrate or 
inhibitor requires further conformational changes of the flap regions. The flexibility of 
the flaps in unliganded protease has been studied by fluorescence experiments 85,86. 
troduction
 
cquired immunodeficiency syndrome (AIDS) has become a worldwide, public 
health threat since 1980. The AIDS patient’s immune system is weakened by infection 
with the human immunodeficiency virus (HIV-1). Maturation of HIV-1 virus requires 
HIV-1 protease to cleave the Gag and Gag-Pol polyproteins to release the structural 
proteins MA, CA, NC and p6, and the enzymes RT, IN and PR. The important role of 
protease in the life cycle of HIV-1 has made it a crucial target for drug design in AIDS 
therapy. 
The 22 kDa HIV-1 protease is a homodimer protein with 99 amino acids on each 
subunit. HIV-1 belongs to the aspartyl enzyme family, with both monomers having 
the conserved active triad residues: Asp25, Thr26, and Gly27. The two protease 
monomers are joined by nonbonded interactions at the N- and C-terminal regions. 
Each monomer has a glycine rich flap region: K45-M-I-G-G-I-G-G-F-I-K55. This 
flap region folds as an anti-parallel β strand that covers the active site. Since the flap 
regions control access to the buried active site, the flexibility of the flap region is 
crucial for enzyme activity and active-site inhibitor binding. Unlike the fully covered 
status in complexes of the protease with inhibit
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NMR relaxation experiments hav the flap region is mobile on a 
microsecond time scale 30. An even higher degree of mobility, on a sub-nanosecond 
tim
 have been approved by the Federal Drug Administration for clinical use in 
fight
e shown that 
e scale, has been shown for the flap tip 48G-G-I-G-G52 30. NMR relaxation 
experiments can detect the overall rate of regional movements of the protease, but this 
approach cannot provide details about the role of each atom in these motions. Such 
information is experimentally difficult to attain. 
Since HIV-1 protease is an important drug target for HIV-1 therapy, the 
development of protease inhibitor drugs has been well studied. Nine protease 
inhibitors
ing AIDS, leading to a significant decrease in the death rate due to AIDS. 
However, due to the high replication rate of the virus and lack of proofreading 
mechanism of its reverse transcriptase, drugs exert a selection pressure on the virus, 
which quickly develops many drug-resistant protease variants. 
The structural basis for these changes in drug-resistant proteases has been studied 
by solving the crystal structures of HIV-1 protease variants. Comparison between the 
structures of wild-type and drug-resistant variant proteases in complex with inhibitors 
partially elucidated how specific protease mutations decrease protease-inhibitor 
binding affinity on the atomic level 37,38. However, static crystal structures cannot 
provide insights into the mechanisms by which mutations change the dynamic 
properties of the protease. Neither can it provide an illustration on the 
enthalpy-entropy compensation observed from the ITC experiments. To fill in the 
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blanks of information gained by experimental methods such as NMR and 
crystallography, computational methods, such as molecular dynamics (MD) 
simulations are used. 
Flap+ is a multiple drug-resistant protease variant with mutations L10I, G48V, 
I54V, and V82A (Figure 3.1). The dissociation constant Kd of DRV-Flap+ binding 
measured by isothermal titration calorimetry experiment is 2.58X10-11 M, for 
DR
o Flap+ protease. The 
resu
V-WT is 4.48X10-12 M.87 The Gibbs free energy change for DRV-WT is 
-15.2kcal/mol, for DRV-Flap+ is -14.2kcal/mol. The ΔΔG is 1 kcal/mol. Both the 
enthalpy and entropy change are remarkably large. The ΔΔH is 14.1 kcal/mol and the 
Δ(-TΔS) is -13.1 kcal/mol. Similar scale of enthalpy-entropy change is observed from 
binding of Flap+ with other inhibitors.87 In order to investigate the molecular 
mechanism that causes these unusual thermodynamics, 20 ns MD simulations were 
performed and analyzed on the apo wild-type protease and ap
lts of comparative analysis show that the apo Flap+ variant is less flexible than 
the wild-type protease probably due to the flap mutations G48V and I54V decreasing 
the flexibility of the protease flap region, but upon complex formation the Flap+ 
variant become more flexible. 
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Figure 3.1: Drug-resistant HIV-1 protease variant Flap+. Mutations are 
highlighted in magenta. 
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Methods 
 
MD simulations were performed using the program Sander in the AMBER 8 
ssisted Model Building with Energy Refinement) package 67. The initial 
coordinates for the MD simulation of the wild-type protease crystal structure were 
provided by 2HB4 81, an apo wild-type HIV-1 protease structure. The initial 
coordinates for the MD simulation of the Flap+ variant were modeled from 2HB4 
using geometry in the AMBER package. Another apo HIV-1 protease crystal structure, 
1HHP, was not used in this study because of its poorer resolution. The first 
conformation of multiple occupancy structures was used in the simulations. Any 
missing side-chain atoms were built back into the structures using the Leap program 
and default geometry in AMBER. All ionizable residues were left in their standard 
states at pH 7.  
For the standard protease residues, atomic partial charges, van der Waals 
parameters, equilibrium bond lengths, bond angles, dihedral angles, and their relative 
force constants were taken from the AMBER database (ff03)57. The explicit solvent 
model was applied to all systems. Each structure was solvated with the TIP3P water 
cubic box to allow for at least 8 Å of solvent on each face of the protease. The vdW 
dimensions for the protease are 44 by 35 by 59 Å. The dimensions of the final 
periodic box are 63 by 55 by 78 Å. The simulation system had approximately 7000 
water molecules, and six Cl- counterions were added to balance the charge of the 
(A
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system. A three-step energy minimiz ss with the steepest descent method 
was used to allow the system to reach an energetically favorable conformation.  
In 
ubsequent sampling MD simulations, each step was 2 fs, and the 
traj
ation proce
the first energy minimization step, all the heavy atoms of the protease were 
restrained with a harmonic force constant of 10 kcal mol-1Å-2. In the second step, only 
the backbone nitrogen, oxygen, and carbon atoms were restrained. In the third step, all 
atoms were allowed to move. Each of the three steps had 2000 cycles. The 
temperature of the energy-minimized system was then gradually raised from 50ºK to 
300ºK in the NVT ensemble. Initial velocities were assigned according to the 
Maxwellian distribution with a random seed. In the thermalization process, heavy 
atoms were restrained with a harmonic force constant of 10 kcal mol-1 Å-2. The whole 
process was 50 picoseconds (50,000 steps, each 1 femtosecond [fs]). A 50 picosecond 
equilibration was then performed in the NPT ensemble without restraining heavy 
atoms. In the s
ectory was recorded every 100 fs. The total simulation time was 20 ns. For the 
thermalization, equilibration, and sampling simulations, the SHAKE algorithm 61 was 
applied to constrain all hydrogen atoms. At every 1 ps, a snapshot was taken to be 
analyzed for the production phase.  
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Results and Discussion 
 
RMSF values of Cα atoms 
One approach to investigating the dynamic features of a system during MD 
simulation is the root-mean-square fluctuation (RMSF) values of Cα atoms for each 
residue, which reflects the backbone mobility of a residue around its average position. 
For both wild-type protease and the Flap+ variant, the regions with the highest RMSF 
values are the flap area and their terminal loops (residues 37-59) (Figure 3.2). The 
most stable areas with the lowest RMSF values in both wild-type protease and the 
Flap+ variant are the nearby active-triad regions (residues 23-28) and the dimer 
interface (residues 3-9, 90-97). These findings are consistent with NMR relaxation 
experiments.30 The flap region residues have the lowest N-H S2 order parameters, and 
the active-triad and dimer-interface regions residues have the highest N-H S2 order 
parameters 30,31. Comparison of the RMSF values between the wild-type protease and 
the Flap+ variant shows that the wild-type protease has overall higher RMSF values 
than the Flap+ variant, which indicates that the wild-type protease is more dynamic 
than the Flap+ variant in solution. 
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Figure 3.2: RMSF values of due highlighted in different 
colors. (A) Wild-type protease. (B) Drug-resistant variant Flap+. Red: >4Å, 
 Magenta: >1.5Å, Blue: <1.5Å. 
(A)
Cα atoms for each resi
Yellow: >3Å, Orange: >2Å,
 
 
(B) 
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Nanosecond snapshots comparison 
To observe conformational changes with respect to time, a snapshot was taken 
every nanosecond and compared with the crystal and pre-equilibrated structures 
re 3.3). From 1 to 6 ns, the wild-type protease backbone conformation has 
similar changes to those of the Flap+ variant. The most significant conformational 
changes can be observed from the diagram at the flap regions, especially at the flap 
tips and external loops where the residues have the highest RMSF values and lowest 
S2 order parameters. From 7 to 17 ns, the Flap+ variant’s flaps on both monomers 
moved slightly towards each other, closer to the active triads than in the crystal 
structure.  
One major conformational difference between the apo protease and liganded 
ase is that the flap regions of the apo protease are in a “semi-open” conformation 
while the liganded protease flaps are fully closed 80-83. Both NMR relaxation 
experiments 88 and free-energy simulations 89 demonstrated that in the apo protease, 
the closed conformation is less favorable for the flaps to adopt than the semi-open 
conformation. The ability of the Flap+ variant to sample conformations more similar 
to the closed state indicates that the G48V and I54V flap mutations have stabilized the 
flap structures.  
After 17ns, the distance between the flap tips of the Flap+ variant started to 
increase again, and the conformations are more similar to those sampled in the first 6 
ns. For the wild-type protease, its flaps gradually opened and exposed the active-site 
(Figu
prote
 95
pocket. During this pro pe protease flaps once 
ag
cess, between 17 to 18 ns, the wild-ty
ain moved towards each other. After 18 ns, the opening of the flaps resumed. The 
enzyme activity of HIV-1 protease is highly influenced by the residues in the flap 
regions 7,90. Since the substrate and inhibitor entrance to the active site requires the 
flaps of the protease to open, the lower flap opening rates of the Flap+ variant 
compared to the wild-type protease observed here could be one reason that the Flap+ 
variant has lower enzyme activity and less binding affinity with inhibitors. 
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Figure 3.3: Snapshots of the simulated structures of wild-type protease and the 
Flap+ variant. (A) Wild-type protease conformations are in cyan. (B) Flap+ 
variant conformations are in magenta. 
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Phi-Psi dihedral angle distribution 
In order to compare backbone flexibility of the wild-type protease and Flap+ 
variant, the phi-psi dihedral angles were plotted for each residue of the proteases for 
each pico-second over the course of the 20 nano-second trajectories. (Figure 3.4A, B) 
As the calculation is on the symmetric apo enzyme, data from each monomer was 
superimposed. Although most of the phi-psi pairs exhibit very similar ensembles 
between the two trajectories, residues W6, R8, G48V, I49, G52 and F53 exhibit 
significant differences (Figure 3.4C). All of these residues, mainly located in the flap, 
sampled larger ranges of phi-psi space in the trajectory of WT compared to Flap+. 
This result possibly indicates that the mutations at G48V and I54V are restricting the 
flexibility of the flap in Flap+. 
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Figure 3.4: Backbone dihedral angles of protease residues 2 to 98. Phi angles on 
the x-axis range from -180 to 180 degrees. Psi angles on the y-axis range from 
-180 to 180 degrees. (A) Wild-type protease. (B) Flap+ variant. (C) Residues have 
significant difference between WT and Flap+. 
(A) 
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(B) 
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(C) 
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Distribution of distance between N-K55 and N-K55’ 
The distance between the Cα atom of residue 55 and the labeled nitrogen atom in 
previous studies [21,22] is similar to the distance between the nitrogen atom of the 
amino group in the original K55 side chain and its Cα atom, which is about 6 Å. The 
distance distribution of the two nitrogen atoms in the K55 side chain from the MD 
simulation can be compared with the results of previous studies, in which the 
inter-flap distance of apo HIV-1 protease was measured by site-directed spin labeling 
pulsed double electron-electron resonance (DEER) electron paramagnetic resonance 
spectroscopy91,92. In those studies, the protease was engineered with the 
Q7K/L33I/L63I mutations to decrease autoproteolysis and C67A/C95A to prevent 
inter-molecule disulfide bond formation. K55 was mutated to cysteine with a 
nitroxide spin-labeled moiety. Their results show that the distance between the two 
labeled nitrogen atoms ranges from 26 to 48 Å. Similarly, the distance of the two 
nitrogen atoms in the apo wild-type protease simulation ranges from 26 to 49 Å 
(Figure 3.5), and for the Flap+ variant, this distance ranges from 24 to 40 Å (Figure 
3.5). The larger range for the wild-type protease indicates that its conformation 
ensemble in solution is more flap-open than that of the Flap+. 
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Figure 3.5: Distribution of distances between the nitrogen atoms in the amino 
group of the K55 side chain and N-K55’ side chain. Distribution data from the 
wild-type protease simulation are in magenta, and from the Flap+ variant are in 
cyan. 
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Dynamic properties of wild-type protease and Flap+ when binding with inhibitor 
To understand the influence of binding with inhibitor on the dynamic properties of 
the wild-type and Flap+ variants, MD simulations of both proteins bound to the 
inhibitor, DRV, were performed and analyzed. When binding with DRV, both the 
wild-type protease and Flap+ are stable, with the same 1.64 Å average RMSD for all 
non-hydrogen atoms. (Figure 3.6) It is very interesting that the flap region of the 
DRV-Flap+ complex is a bit more mobile than the DRV-WT complex. The average 
RMSD of residues 45 to 55 for the WT protease is 1.91 Å and for the Flap+ is 2.45 Å, 
with average RMSD of residues 45’ to 55’ of 1.85 Å and for Flap+ of 2.28 Å. For the 
apo protease, the flap region of the WT protease is more flexible and mobile than the 
Flap+ according to the analysis above. The RMSF of the Cα atoms of the protease 
also supports this conclusion. In the apo form, the Cα atoms of the WT in the flap 
region are more fluctuated than the Flap+ variant (Figure 3.7A, B). When binding 
ith DRV, the Cα atoms in the flap region are significantly decreased compared to 
their apo form. The atoms in the WT are slightly less fluctuated than the Flap+ variant. 
(Figure 3.7C, D) The simulated structure at the end of 20ns simulations of the 
DRV-Flap+ complex has deviated more extensively from its crystal structure than the 
DRV-WT complex. (Figure 3.8) The mutations of Flap+ affect protease dynamics 
destabilizing the DRV complex. 
w
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Figure 3.6: RMSD of protease atoms with respect to their corresponding crystal 
structures during the 20 ns MD simulations. Data from the DRV-WT simulation 
is in blue, and data from the DRV-Flap+ simulation is in red. (A) RMSD of all 
protease atoms except hydrogen atoms. (B) RMSD of atoms in residues 45 to 55. 
(C) RMSD of atoms in residues 45’ to 55’. 
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(A)  
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Figure 3.7: RMSF values of the Cα atoms for each residue in the MD simulation. 
(A) APO wildtype (B) APO Flap+ variant (C) DRV-WT complex (D) DRV-Flap+ 
complex 
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Figure 3.8: Crystal structures (left) of DRV-WT (A) and DRV-Flap+ (B) and 
their structures after 20ns MD simulations (right). 
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Summary 
 
In this study, I performed molecular dynamics simulations to investigate and 
are dynamic changes in the drug-resistant protease variant Flap+ to those of the 
wild-type protease. The flexibility of the protease flaps is important to enzyme 
activity since the flaps control access of the substrate to the protease active site.  The 
results indicate that the wild-type apo-protease is more flexible than the Flap+ variant, 
especially in the flap region. However, when wild-type and the Flap+ protease bind 
with the inhibitor DRV, the DRV is more stable in the wild-type active site, despit e 
similar overall flexibility of the backbones of the two enzymes.  Yet, when the flap 
dynamics are compared, the flaps are more flexible in the complex of Flap+ than in 
the wild-type complex.  Although the binding free energy measured by calorimetry 
experiments shows that DRV binding with a higher affinity to the WT, the Flap+ 
exhibits a more favorable change in entropy.  The value of ΔΔS, the entropy change 
of Flap-DRV binding with respect to the entropy change of WT-DRV, is 45 
cal/(mol·T). The MD simulation results indicate that the Flap+ variant binding with 
DRV compared to WT is likely the case of a less flexible apo protease binding with 
DRV and forming a more flexible, less optimal, complex. Assuming the level of 
disorder of a system is positively correlated with its entropy, the predicted entropy 
change of Flap+-DRV binding compared to WT-DRV binding from MD simulation 
result is larger in agreement with calorimetric results.  Thus MD simulation provides 
comp
e th
 111
a rationalization for the experimentally observed thermodynamic data.
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Chapter IV 
 
 
Discussion 
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Abstract 
In this chapter, the following topics, eithe as further analysis or future directions 
based on the Chapter II and Chapter III, are being discussed. A summary on this 
thesis is given at the end of this chapter. 
 
Further discussion of calculations and decompositions of changes in 
protease-inhibitor binding free energy  
1. Free-energy component an  wild-type and 
drug-resistant variants and comparison with those of DRV. 
2. Analysis of a representative conformer to elucidate changes in free-energy 
components of protease-DRV binding. 
3. Comparison with the published results of free energy calculations on HIV-1 
protease binding with protease inhibitors 
 
NMR relaxation experiments on apo protease dynamics 
1. Significance of doing NMR relaxation experiments to compare dynamic 
properties of apo wild-type protease and apo Flap+ protease variant  
2. Necessity of introducing mutations L33I, L63I, C67A and C95A to prepare stable 
protease samples for NMR experiments – HSQC of original wild-type 
3. HSQC of new construct WTNMR; ITC experimental results of WTNMR and 
Flap+NMR  
r 
alysis of APV binding with
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4. Preliminary results of NMR relaxation experiments on Flap+NMR and comparison 
with the published WTNMR data   
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Further discussion of calculations and 
decomposition of change in protease-inhibitor 
binding free energy 
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Free-energy component analysis of APV binding with wild-type and 
drug-resistant variants and comparison with those of DRV 
APV (amprenavir), which is the basis for the design of DRV (darunavir), differs 
from DRV on the single-ring tetrahydrofuranyl (THF) moiety with stereochemical 
change instead of bis-THF moiety on DRV
forms strong interactions with protease residues D29 and D30 in the crystal structure 
of the DR p+ and 
AC
APV is -12.6 kcal/mol for +, and -11.58 kcal/mol 
for ACT 93. Crystallographic analysis 93 shows, for the ACT (V82I, I84V) variant, 
both APV and DRV lose favorable vdW contacts with residue 84, which might be the 
major reason of the loss in binding free energy with protease compared with wild-type. 
Another crystallographic study87 comparing the crystal structure of DRV/APV 
complexed with the wild-type and Flap+ proteases shows that the Val to Ala mutation 
on residue 82 decreases the favorable vdW interaction between the protease and 
inhibitors. Comparing the binding of APV and DRV with protease will elucidate how 
these similar inhibitors respond to drug-resistant mutations, thus providing insights to 
benefit the design of new inhibitors with higher binding affinity and less susceptibility 
to drug-resistant mutations. Here I applied the same free-energy calculation and 
decomposition scheme described in Chapter II to APV-protease binding and 
compared the results with DRV-protease binding. 
 (Figure 4.1). The bis-THF group of DRV 
V-protease complex 93, and these interactions are preserved in the Fla
T variants (Chapter II). The binding free-energy change between protease and 
 wild-type, -11.90 kcal/mol for Flap
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The calculated absolute binding free-energy changes of APV binding
Flap+ and ACT are in good agreement with the experimental da
 with WT, 
ta. The 
pred
e 
V 
propyl 
ction energy.  
icted/experimental binding free energy change is -15.5/-12.6 kcal/mol for 
APV-WT, -12.5/-11.9 kcal/mol for APV-Flap+ and -12.1/-11.6 kcal/mol for 
APV-ACT. The contributions from different kinds of interactions to the absolute 
binding free-energy change and the relative binding free-energy change are similar to 
the distributions of the DRV-protease binding free-energy changes (Figure 4.2A, B). 
The contribution from vdW interactions is dominant in the total free-energy chang
(Figure 4.2C, D). The favorable Coulombic interaction energy is largely cancelled by 
the polar solvation energy.  
In terms of each atom’s contribution to the binding free-energy change, the DRV 
binding energy profiles with the two drug-resistant variants Flap+ and ACT are 
similar (Figure 4.3A), whereas APV has different profiles with the two variants 
(Figure 4.3B). Changes in vdW interaction energy for each moiety of the two 
inhibitors, their percentage loss with respect to the same atoms binding with WT 
(Chapter II), and their percentage loss with respect to all inhibitor atoms binding with 
WT are shown in Table 4.1. In the case of DRV, the loss of favorable vdW interaction 
energy for both drug-resistant variants is mainly on the 4-amino phenyl and isopropyl 
groups. In the case of APV binding with ACT, the energy profile is similar to DR
binding. In the case of APV binding with Flap+, the tetrahydrofuranyl and iso
groups have the most significant loss in vdW intera
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Figure 4.2: (A) Binding free-energy components of DRV-WT, DRV-FLAP+ and 
-ACT. (B) Binding free-energy components of APV-WT, APV-FLAP+ and 
PV-ACT. (C) Loss of binding free-energy components of DRV with FLAP+ 
nd ACT compared to that with WT protease. (D) Loss of binding free-energy 
ponents of APV with FLAP+ and ACT compared to that with WT protease. 
DRV
A
a
com
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Figure 4.3: (A) The four moieties of DRV. (B) The four moieties of APV. (C) 
vdW interaction energy for each heavy atom of DRV with protease. Energy 
changes of DRV-FLAP+ with respect to the WT are shown in magenta and 
energy changes of DRV-ACT with respect to the WT are shown in cyan. (D) 
vdW interaction energy for each heavy atom of APV with protease. Energy 
changes of APV-FLAP+ with respect to the WT are shown in red and energy 
changes of APV-ACT with respect to the WT are shown in blue. 
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Table 4.1: Loss of Van der Waals’ Interaction Energy for Different Moieties of 
DRV and APV   
DRV 
4–Amino 
Phenyl 
Group 
Isopropyl 
Group 
Benzyl Ring 
bis- 
Tetrahydrofu
ranyl 
kcal/mol* 0.72 0.36  0.59 0.17 
%** 12.3 12.1 12.8 2.7 -Flap+ 
%WT*** 3.7 1.8 3.0 0.9 
kcal/mol 1.11 0.83 0.30 0.20 
% 18.9 28.0 6.5 3.2 DRV-ACT 
%WT 5.6 4.2 1.5 1.0 
APV 
4–Amino 
Phenyl 
Group 
Isopropyl 
Group 
Benzyl Ring 
Tetrahydrofu
ranyl 
DRV
kcal/mol -0.15 0.93 0.43 1.52 
% -3.2 33.2 9.2 31.7 APV-Flap+ 
%WT -0.9 5.5 2.5 8.9 
kcal/mol 1.13 0.17 0.28 0.16 
% 23.9 6.1 6.0 3.3 APV-ACT 
%WT 6.6 1.0 1.7 0.9 
* The energy change compared to the same atoms binding with WT 
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** Percentage of energy loss with respect to atoms of the same moiety binding with 
WT 
*** Percentage of energy loss with respect to all inhibitor atoms binding with  WT 
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The contribution of charge interactions to APV-protease binding and 
DRV-protease binding 
each residue of the drug-resistant variants, changes in Coulomb interaction energy 
(ΔΔGELE) and changes in solvation energy (ΔΔGGB) are highly correlated (Figure 
4.4A, B). The linear regression analysis of ΔΔGGB with respect to ΔΔGELE shows their 
correlation coefficient r is -0.98 for Flap+ and -0.97 for ACT. The same high 
correlation applies to the binding of these two variants with APV. (Figure 4.4C, D). 
The correlation coefficient r is -0.95 for Flap+ and -0.94 for ACT. The high negative 
correlation between the ΔΔGGB and ΔΔGELE partially explains the how the change of 
total charge interaction energy become a minor factor in the total change of binding 
free energy compared to the vdW interactions. Interestingly, a previous free energy 
component analysis shows that, compared to the total predicted binding free energy, 
the predicted contribution from electrostatic interaction has a higher correlation with 
the experimental binding free energy.94 Recently a similar analysis from the same 
group on interactions between HIV protease and inhibitors yields the conclusions that 
the total theoretical binding energy is in better agreement with the experimental data, 
although the free energy component from charged interactions itself is also in good 
correlation with experimental binding free energy.95 This difference might have 
resulted from, as the author pointed out, the different environments of the two 
systems.95 The former calculation is on the large solvated protein surface while the 
In Chapter II I showed that, compared to WT protease binding with DRV, for 
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latter calculation on HIV protease is on a relatively small and buried binding pocket. 
In attempt to find those residues which have a significant charge interaction energy 
chan gy ge, a cutoff of 0.2 kcal/mol is set for the change in total charge interaction ener
(sum of ΔΔGGB and ΔΔGELE). Residues with a change in total charge interaction 
energy over 0.2 kcal/mol are labeled in Figure 4.4. The change of the charge 
interaction energy differs in detail for the binding of DRV and APV with Flap+ and 
ACT (Table 4.2). A further investigation on how these residues changed their 
coulombic interactions with the inhibitors or how they changed the solvation energy 
upon binding with inhibitors will be valuable to improving the design of inhibitors 
with optimal charge distribution to maximize the binding energy of charge 
interactions with protease. 
 127
Figure 4.4: Correlation between ΔΔGELE and ΔΔGGB of each residue. The 
highlighted residues are with total charge energy change (ΔΔGELE+ΔΔGGB) 
larger than 0.2kcal/mol or less than -0.2kcal/mol. (A) Energy difference between 
DRV-FLAP+ and DRV-WT. (B) Energy difference between DRV-ACT and 
DRV-WT. (C) Energy difference between DRV-FLAP+ and DRV-WT. (D
Energy difference between DRV-ACT and DRV-WT. 
(A) 
                                    
) 
 
 128
(B) 
 
 
 129
(C) 
 
 130
(D) 
 
 131
Table 4.2: Residues with change in charge interaction energy larger than 0.2 
kcal/mol in drug-resistant variants Flap+ and ACT 
 
ΔΔGCharge > 0.2 ΔΔGCharge < 0.2  
ΔΔGELE> 0 
ΔΔGGB> 0 
ΔΔGELE> 0
ΔΔGGB< 0
ΔΔGELE< 0
ΔΔGGB> 0
ΔΔGELE< 0
ΔΔGGB<0
ΔΔGELE> 0 
ΔΔGGB< 0 
ΔΔGELE< 0
ΔΔGGB> 0
DRV-Flap+ 
 A28, V48, 
R87, V48’
D29 G27’ I50’, R8’ G49’ 
APV-Flap+ A28, A82’ I47’  T80’, T26’ V32’ D29, D30 G49 
DRV-ACT G49 
 T82’, G27, 
T26 
D25’ D29’ I47’, T80’
APV-ACT R8 G49’, D30 T82, T26’, D29, G49 D25 I50, G48 
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Using a representative conformer to elucidate the free-energy change of Fl
and ACT binding with DRV 
ap+ 
The MM-GBSA f method and the following free-energy 
component n e h x
sampled du la im he  re t
ensemble averag of the ic properties of the system. The average 
structure of the conforme  simulations reflects the most frequently sampled 
 o f th . F e-ene prote
residue, one can observe that most of t esidues that contribute to binding 
with inhibitors, and have a significant free gy change on drug-resistant variants, 
turally e to t  b C  repr tive 
onformer which can be used to elucidate the calculated energetic properties should 
be able to mostly represent the ensemble of sampled positions of these protease atoms. 
For each trajectory of the MD simulation of protease-inhibitors complex, an average 
structure was generated. Each frame of the trajectory is superimposed on the average 
structure by the proteases atoms within 7 Å of any inhibitor atom. The frame with the 
lowest RMSD was chosen as a representative structure to illuminate changes in 
binding free energy between the drug-resistant variants and wild-type protease. In 
Figure 4.5, the protease atoms which were within 7 Å of atoms of certain inhibitor 
moieties are shown.    
 
ree-energy simulation 
s analysis are based on co formers of th  protease-in ibitor comple  
ring molecu r dynamic s ulations. T  calculated sult represen s an 
e thermodynam
rs from MD
positions f each atom o e system rom the fre rgy decomposition by ase 
he protease r
-ener
are struc  clos he inhibitor inding site. ( hapter II) A esenta
c
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For the WT-DRV complex, the 4-amino phenyl group of DRV is surrounded by 
protease residues G27’ to V32’, I47’ to G49’, I84’ and I50. (Figure 4.5A) Some 
de-chain atoms from V82’, V82, L76’ and I85’ also significantly contribute to the 
vdW  
gion. 
 
 
 
 
e chain than Val in the WT protease cannot be compensated 
si
 interactions with this group. In the Flap+ and ACT cases, the vdW interactions
are maintained between this group and the protease residues located in the flap re
Furthermore, the larger side chain from mutation G48’V in the Flap+ variant is not 
involved in interactions with this part of DRV. In the DRV-Flap+ complex, I84’
maintains vdW contacts while A82 and A82’ do not. The loss of vdW interaction 
energy is mainly in the G27’ to V32’ region of Flap+. In the DRV-ACT complex, the 
G27’ to V32’ region maintains its vdW interactions with the 4-amino phenyl group of
DRV. The major loss is at position 84’, which is Ile in the WT protease and Val in the
ACT variant.  
In the DRV-WT complex, the isopropyl group of DRV is flanked by the two 
catalytic aspartic acids D25/D25’ and the adjacent residues from T26’ to D29’, flap 
residues G48’ to I50’, and the P1 loop residues V82 and I84. Mutation V82A in Flap+
and I84V in ACT have a similar impact on this isopropyl group. A smaller side chain 
leads to the isopropyl group sliding towards the P1 group, and losing its vdW 
interactions with D25’ to D29’.  
The major difference between the benzyl ring (group C) in DRV-WT and 
DRV-Flap+ is at position 82. The loss of favorable vdW contact due to Ala in the 
Flap+ being a smaller sid
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by a
e 
e 
le to 
dding a vdW contact from G48V in the DRV-Flap+ complex. 
Among the 4 moieties of DRV, the bis-THF group is the one experiencing th
least vdW interaction energy loss. This group is well packed with the residues R8’, 
I50’, I/V84, G27 to V32 and I47 to G49. These key residues maintain their 
interactions with DRV in the drug-resistant variants Flap+ and ACT.  
From these observations and the free-energy decomposition data shown in Tabl
4.1, one can conclude that the 4–amino phenyl and isopropyl groups are susceptib
P1 loop mutations (V82A/T, I84V), and the benzyl ring is more sensitive to flap 
mutations. The bis-tetrahydrofuranyl group is the least susceptible part of DRV to 
drug-resistant mutations. 
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Figure 4.5: Protease atoms making major contributions to vdW interactions with 
different moieties of DRV. (A) The 4-amino phenyl group. (B) The isopropyl 
group. (C) the benzyl ring. (D) the bis-tetrahydrofuranyl ring. 
(A) 
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Flap+ 
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(C) 
 
Flap+ 
WT 
ACT 
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(D) 
 
 
WT 
Flap+ 
ACT 
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NMR relaxation experiments on apo 
protease dynamics 
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Significance of doing NMR relaxation experiments to compare dynamic 
properties of apo wild-type protease with the apo Flap+ protease variant 
 
The interesting high entropy-enthalpy compensation of the Flap+ protease 
vari
studies87 or free-energy tical to protease 
nction as shown in NMR relaxation experiments 30,31,88, molecular dynamics 
simulations29,96, and site-directed spin labeling experiments91,92,97. The flap mutations 
G48V and I54V were shown by theoretical studies (Chapter III) to greatly influence 
flap and even protease dynamics. No experiments have directly shown how much 
influence these mutations have on protease dynamic properties. In order to understand 
the mechanism of the dynamic properties difference between the WT protease and the 
Flap+ protease, NMR relaxation experiments were employed to study the apo Flap+ 
protease dynamics behavior in solution. 
ant binding with DRV and APV87 could not be elucidated by crystallographic 
 simulation methods. Flap dynamics is cri
fu
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15N labeled protease expression, purification and refolding 
 
HIV-1 protease was expressed in Escherichia coli strain BL21-Gold(DE3)pLysS 
com
 in 
he 
s 
d in 50% acetic acid to extract protease. 
Proteins with different molecular weight were separated by size exclusion 
chromatography on a 2.1 L Sephadex G-75 superfine column. Refolding was 
accomplished by diluting the protease solution into a 100-fold excess of refolding 
buffer. Excess acetic acid was removed through dialysis. 
petent cell using a T7 expression system. The bacteria were glown in LB or 
TB(Table 4.3) at 37°C. When OD600 value of the culture reached 0.4, the bacteria 
were separated from the LB culture by centrifugation. The pellet was resuspended
1L cold (4°C-10°C) wash buffer (Table 4.4). The bacteria were separated from t
wash buffer by centrifugation and resuspended with 250 mL 15N minimal medium 
(Table 4.5). The M9 bacterial culture was glown at 37°C for 10 to 20 min. Afterward
protease expression is induced with 2 mM IPTG for 4 hours. (Figure 4.6) After 
induction, the culture was centrifuged and the bacteria pellet was separated and 
stocked at -80°C. The protease was contained in the inclusion body in the bacteria 
pellet. After the bacteria was lysed, the inclusion bodies were isolated by 
centrifugation and the pellet was dissolve
 142
Table 4.3 Recipe for 1 L LB medium (autoclaved) 
Tryptone 10 g 
Yeast Extract 5 g 
NaCl 5 g 
1M NaOH 1 ml 
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Table 4.4 Recipe for 1 L of wash buffer (autoclaved) 
KH2P 3.0O4  g 
Na2H 12.
NaCl 0.5 
1 M claved) 2.0
 M CaCl2(autoclaved) 0.1 ml 
H adjusted to 7.2 with NaOH 
 
 
PO4·7H2O 8 g 
g 
MgSO4(auto  ml 
1
p
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Table 4.5 Recipe for 1 L of minimal medium and 1 L of 5 X M9 Salts (autoclaved) 
Minimal medium 
l 
 
5 X M9 Salts 200.0 m
D-glucose Stock (20 g/100 ml) l 
 
20.0 m
1 M MgSO4(autoclaved) 2.0 ml 
1 M CaCl2(autoclaved) 0.1 ml 
 
5 X M9 Salts (autoclaved)  
H4Cl 5.0 g N
KH2PO4 15.0 g 
Na2HPO4·7H2O 64.0 g 
NaCl 2.5 g 
pH adjusted to 7.2 with NaOH 
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Figure 4.6 15N labeled protease expression samples on 16% SDS PAGE. Pre: 
sample before IPTG i ker for HIV-1 protease. 2, 4, 6, 8, 9, 12: 
ples after different hours IPTG induction. 
nduction. M: mar
expression sam
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Necessity of introducing mutations to prepare stable protease samples for N
experiments – HSQC of original wild-type 
 
MR 
In studies of the active form of HIV-1 protease, a critical problem that has to be 
solved in preparing protease samples for NMR is the autoproteolysis. HIV protease 
with the Q7K mutation, which is supposed to decrease self-cleavage98, still shows 
high levels of autoproteolysis in 15N-1H HSQC spectra (Figures 4.7A and 4.7B). The 
sample contained 67 M Q7K, 5% D2O, 5mM DTT in 20mM sodium phosphate 
buffer.30,31,99,100 The pH was adjusted to 5.8.30,31,99,100 The HSQC spectrum was 
obtained using a 700 MHz magnet at 293 K. The first spectrum was taken on August 
, 2005 and the second on August 4, 2005 by J. Peng in University of Notre Dame. 1
 147
Figure 4.7: 15N-1H HSQC spectra of Q7K protease. (A) Spectra recorded on Aug 
1st, 2005. (B) Spectra recorded on Aug 4th, 2005. 
(A) 
 
(B) 
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To evaluate the relative velocity of degradation of the signals, HSQC spectra 
were recorded from August 5 to August 8. The amplitudes of the major peaks from the 
C spectrum were integrated and simulated the decay with respect to time using 
the following formula:  
 
A is the integrated amplitude of a potential peak for a residue (based on the 
chemical shift). Setting the time that the first spectrum is taken as 0 h, the other time 
points are 75, 97, 119, 145, and 165 h.  
0
t
HSQ
A A e
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Figure 4.8: The simulated decay of HSQC spectrum of Q7K. 
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Most of the peaks have degrading amplitudes (β<0). (Figure 4.8) To improve 
stability of the protein, 2 mutations were introduced: L33I and L63I. These two 
mutations have been shown to significantly increase protease stability and retain its 
enzyme activity 98,101. Two cysteine residues of the protease at positions 67 and 95 
were mutated to alanines to prevent potential formation of intermolecular disulfide 
bonds. These mutations have frequently been employed in NMR research to study 
protease dynamics 30,31,88,99,100.  
In the following discussion, variant WTNMR refers to protease Q7K, L33I, L63I, 
C67A and C95A (Figure 4.9).Variant Flap+NMR refers to protease Q7K, L33I, L63I, 
C67A, C95A, L10I, G48V, I54V and V82A. The plasmid of WTNMR was prepared by 
Dr. Jennifer Foulkes-Murzycki and the plasmid of Flap+NMR was prepared by Ellen 
Nalivaika. 
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Figure 4.9: Structure of WTNMR protease variant with the new mutations 
highlighted 
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HSQC experiments on the newly constructed protease WTNMR 
 
The HSQC spectra for a sample of WTNMR are shown in Figures 4.10. The 
sample contained 100 M WTNMR and 5% D2O in 20 mM sodium phosphate buffer at 
pH 5.8.30,31,99,100 The HSQC spectrum was measured on a 600 MHz magnetic at 293 K. 
The first spectrum was obtained on Feb 15, 2006 and the second on Feb 21, 2006 by 
R. Vadrevu in University of Massachusetts, medical school in Worcester. 
Compared with the HSQC spectrum of Q7K, the new construct significantly 
increases protease stability. 
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Figure 4.10: HSQC spectra of a WTNMR sample. (A) Spectra recorded on Feb 
15th, 2006. (B) Spectra recorded on Feb 21st, 2006. 
(A) 
 
(B) 
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ITC experimental results of WTNMR and Flap+NMR proteases binding with DRV 
 
Isothermal titration calorimetry displacement was used to measure the binding 
affinity of DRV with WTNMR and Flap+NMR. The results are compared with the ITC 
data for WT and Flap+ variants. All the conditions and steps of the WTNMR and 
Flap+NMR ITC experiments followed those used in the WT and Flap+ ITC 
experiments87,93 for parallel comparison. Pepstatin was used as a binding competitor 
of DRV to protease.  
The binding affinity and enthalpy change of DRV with WTNMR and Flap+NMR were 
measured using competitive displacement ITC experiment on a VP- isothermal titration 
calorimeter at temperature 293 K. The measurements were done in buffer at pH 5.0 
consisted of 10 mM sodium acetate, 2.0% dimethyl sulfoxide, and 2 mM TCEP 3 25 
µM protease solution was saturated with twenty-nine 10 µl injections of 0.3 mM 
pepstatin. Pepstatin was then displaced from protease by adding twenty-nine 10 µl 
injections of 0.25 mM DRV. Software Origin7 (Figure 4.11) was used to process the 
data to get the binding affinity and enthalpy of the interaction between the protease and 
DRV. 
The ITC experiments results for WT, Flap+, ACT, WTNMR and Flap+NMR are 
shown in Table 4.6. The introduced mutations did change the binding affinities which 
were 0.32 kcal/mol for the WT and 0.55 kcal/mol for the Flap+. The entropy and 
enthalpy changes between WTNMR and Flap+NMR are in agreement with the profiles of 
.9
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WT and Flap+ variants. (Figure 4.12) The very high enthalpy-entropy compensation 
was observed from the ITC results. 
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Figure 4.11: ITC displacement experiments (A) and (B) of WTNMR binding with 
DRV using pepstatin as competitor protease binder.  
(A) 
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(B) 
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Table 4.6: Thermodynamic data of WTNMR and Flap+NMR binding with DRV 
measured by displacement isothermal titration calorimetry experiments. 
 
 ΔH (kcal/mol) ΔG (kcal/mol) -TΔS (kcal/mol) ΔS (cal/[mol·T]) 
DRV-WT -12.1±0.8 -15.2±0.1 -3.1±0.9 10.6±2.7 
DRV-Flap+ 2.0±0.6 -14.2±0.2 -16.2±0.8 55.3±2.5 
Exp1 -11.6±0.1 -15.0±0.1 -3.4±0.2 11.6±0.5 
Exp2 -11.6±0.1 -14.8±0.1 -3.2±0.2 11.0±0.5 
DRV- 
WTNMR 
Avg -11.6±0.1 -14.9±0.1 -3.3±0.2 11.3±0.5 
Exp1 -1.9±0.2 -13.8±0.1 -11.9±0.3 40.6±1.0 
Exp2 -1.6±0.2 -13.5±0.1 -11.9±0.3 40.6±1.0 
DRV- 
Flap+NMR 
Avg -1.8±0.3 -13.6±0.1 -11.9±0.3 40.6±1.0 
DRV-ACT -10.0±0.1 -13.6±0.1 -3.6±0.2 12.5±0.7 
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Figure 4.12. The WTNMR and Flap+NMR also have large scale of enthalpy and 
entropy change.   
` 
  
Flap+NMR/WTNMR 
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Preliminary results of NMR relaxation experiments on Flap+NMR 
comparison with pu
and 
blished wild-type data  
 
To date, the T1, T2 and NOE data of apo Flap+NMR backbone amide were 
collected from an 800 MHz magnet by J. Peng in University of Notre Dame. The 
Flap+NMR protease sample was 250 μL solutions in Shi imer 
concentrations 400 μM in 20 mM sodium phosphate with 2% D2O. Spectra were 
recorded at temperature 293K. 15N T1's were measured using relaxation delays of 32, 
56, 88, 320, 640, and 960 ms and 8, 16, 128, 256, 384, 512, and 640 ms. T2 were 
measured with relaxation delays of 8, 16 24, 32, 56, 88, and 120 ms, and of 6, 12, 18, 
24, 36, 48, and 60 ms, respectively. 15N–1H NOE experiments were performed using a 
water flip-back sequence.31 NOE values were measured by taking the ratio of peak 
intensities from experiments performed with and without 1H presaturation. All data 
were processed using the TOPSpin software package30 and peak heights measured in 
the processed spectra were fitted with a two-parameter exponential function to extract 
relaxation rates. Errors in T1 and T2 (or T1ρ) were determined by Monte-Carlo 
simulations31. 
As a preliminary comparison, I superimposed the HSQC spectrum of Flap+NMR 
onto the HSQC spectrum of WTNMR with residues assignment publised31. Most of the 
residues have chemical shifts. Several residues have relatively isolated peaks on the 
spectrum and might be identified. (Figure 4.13A) Their T1 and NOE values are 
gemi microcells at d
 161
compared from the WTNMR and Flap+NMR. (Figure 4.13B, C) The T1 and NOE show 
different values indicating change of the protease dynamics. Residues have large 
chem ight have larger difference in dynamics. ical shift m
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Figure 4.13. (A) Superimposition of the HSQC spectra of Flap+NMR on the
WTNMR spectra with residues assignments. The cycled residues are assumed t
the same residue in Flap+NMR and WTNMR. (B) T1
 
o be 
 values of residue of the 
Flap+NMR and WTNMR. (C) NOE values of residue of the Flap+NMR and WTNMR.   
(A) 
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(B) 
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Summary 
 
The scope of this study was to understand how drug-resistant mutations change 
the thermodynamic and dynamic properties of HIV-1 protease. Thereby gaining 
knowledge which could be applied in the structure-based drug design of HIV-1 
protease inhibitors and make them more effective against drug-resistance. Comparing 
the crystal structure of APV bound to wild-type protease and a drug-resistant protease 
variant, King et al. found that the mutation I84V has decreased the vdW interaction 
between APV and the drug-resistant variant, which might account for the loss of 
binding affinity between APV and the drug-resistant variant. By analyzing the ITC 
experiments results, Irene et al. suggested that the drug-resistant mutations change the 
shape of the active site. The very flexible substrates are less susceptible to the change 
than the synthetic inhibitors102, which might enable the drug-resistant protease variant 
to still recognize the substrate while having less binding affinity with the synthetic 
inhibitors. Comparing the trajectories from MD simulations on the wild-type protease 
and the V82F/I84V protease variant, Perryman et al. suggested that the mutations 
change the equilibrium between the flap-semiopen and closed conformations could be 
one aspects of the protease drug-resistant mechanism96. To study the changes in 
thermodynamic properties of inhibitor binding with drug-resistant mutations, I 
performed free-energy calculations and decomposition using the crystal structure 
atomic coordinates as input and thermodynamic data from isothermal titration 
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calorimetry experiments as control. The predicted binding free energy was in good 
agreement with the ITC experimental data. 
ergy 
 
r 
 
e not 
ghout 
p with 
 
The thermodynamic integration method, developed from statistical mechanics, 
was shown to be advantageous in precisely predicting the relative binding free-en
change (Table 2.4). Applying free-energy decomposition to classical energy 
simulation methods such free energy perturbation and thermodynamic integration has 
been questioned. The application of such methods usually calculates through the 
thermodynamic cycle (Chapter II, Methods) which requires the quantity to be a state
function such as Gibbs free energy. The free-energy components defined by eithe
different types of molecular interactions (ie. vdW, electrostatic) or contributions from
different protein residues or ligand atoms, are no longer state functions which are not 
path dependent 103-105. The MM-PB/GBSA method is a faster but less accurate 
alternative to traditional perturbation methods. This method has increased in 
popularity to calculate absolute binding free-energy changes associated with 
biomolecular recognition and relative free energies of different conformations 24-28. 
The MM-PB/GBSA method is also convenient for carrying out free-energy 
component analysis. The free energy analysis of protease-inhibitor binding in Chapter 
II and the further discussions here reveal that a drug-resistant mutation at a residu
only changes its interaction with an inhibitor, but also propagates changes throu
the active site to other residues interactions with the inhibitor. 
The design of DRV from APV, which replaced the tetrahydrofuranyl grou
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the bis-tetrahydrofuranyl group, successfully increased the binding affinity of the dr
with the protease.54,55 Although DRV lost bin
ug 
ding affinity with the drug-resistant 
varia
e 
 to 
 
s 
esistant 
nts Flap+ and ACT, it still binds better than APV with these variants.87,93 From 
energy decomposition of the different moieties of DRV, the bis-tetrahydrofuranyl 
group maintains its vdW interaction energy even in the drug-resistant proteas
variants. The design of new inhibitors from the DRV structure should consider 
modifying the 4-amino phenyl and isopropyl groups to reduce DRV susceptibility
mutations in the P1 loop. Recently, several new DRV-based compounds have been 
synthesized by chemists in Schiffer’s group. These compounds have been shown to
have overall better binding affinity with several typical drug-resistant variants (Figure 
4.14). All these compounds are larger than DRV at the 4-amino phenyl and isopropyl 
groups, which generate more vdW interactions with the protease. These change
could be the molecular basis for these analogues being more tolerant to drug-r
mutations than DRV. 
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Figure 4.14: Antiviral experiments performed by Monogram show the new DRV 
analogues have better binding affinity than DRV to drug-resistant protease 
variants 
 
 
1 nM 
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The Gibbs free energy calculations results were highly correlated with the 
experimental result. (Chapter II) The calculation of entropy change remained as 
challenge.
a big 
 The calculations of the change of Gibbs free energy by TI or FEP methods 
only rely on the sampling of the low energy regions of the phase space. Using TI and 
FEP to calculate the change of entropy required the sampling of all the 
configurational space which is hard to achieve with current hardware techniques. In 
MM-PB/GBSA methods, some of the entropy changes (ΔSrot, ΔStran, ΔSvib) of the 
protease-inhibitor ing were calculated explicitly. These terms can not be 
compared with the experimental binding entropy change directly. Part of the entropy 
change was coupling with the solvation model and calculated implicitly associating 
with the polar (PB or GB) solvation energy change or the non-polar solvation energy 
change. 
In Chapter III the dynamics of two apo proteases, the wild-type and a 
drug-resistant variant Flap+, were compared in silico. 20 ns molecular dynamic 
simulations were performed and analyzed. The molecular mechanics properties 
indicate that the apo Flap+ protease variant is less dynamic than the wild-type 
protease. Molecular dynamic simulations can elucidate protease dynamics on an 
atomic level, which is difficult to access by any experimental methods. NMR 
experiments can provide dynamic information about the protease on a longer time 
scale, e.g., microseconds, which is hard to accomplish in standard MD simulation 
with explicit solvent. NMR relaxation experiments require high concentration 
 bind
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protease samples, 300 to 500 μM of dimer concentrations are preferable. Under these 
high concentration conditions, protease, which is its own cleavage substrate, 
undergoes severe autoproteolysis. Thus, new constructs (e.g., Flap+NMR) were 
synthesized to prepare stable NMR samples. The thermodynamic properties of these 
new constructs in binding with DRV were measured by ITC experiments and 
compared to the original wild-type and Flap+ variant. R1, R2 and NOE data of 
Flap+NMR were collected from an 800 MHz magnet. To identify all peaks, assignment 
experiments were needed. Thus, all the relaxation data will be compared to the 
published wild-type data30,31,99 to understand how the drug-resistant mutations 
changed the apo protease dynamics. 
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In summary, the molecular mechanism of HIV-1 protease drug resistance is 
complicated and comprehensive investigation is needed. Computational methods such 
as free energy analysis and MD simulation can provide thermodynamic and dynamic 
insights about protease variants on an atomic level. These computational data 
complement the experimental calorimetry and NMR, and by obtaining a series of 
datasets from a series of parallel experiments the details of how inhibitor binding is 
altered by drug resistance can be elucidated. The knowledge from correct modeling 
will enrich understanding of how drug-resistant mutations change the energetic and 
dynamic characteristics of HIV-1 protease and help to develop protease inhibitors that 
bind more tightly to the protease and are more tolerant of drug-resistant mutations. 
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